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Abstract
Introduction: This thesis aims to advance magnetic resonance imaging (MRI) for imaging
cellular therapeutics. Traditional, proton-based, MRI provides detailed anatomical images,
particularly of soft tissue. However, in order to obtain information at a cellular level
specialized imaging agents are required to detect the cells of interest. Perfluorocarbons
containing non-radioactive fluorine-19 (19F) are both biologically safe and MR sensitive.
Methods: Pre-clinical

19

F-MRI was implemented on a Varian 9.4T MRI scanner, using a

dual 19F/1H-tuned birdcage volume coil. Mesenchymal stromal cells (MSC) were pre-labeled
with a commercial, FDA approved

19

F-perfluorocarbon emulsion, then implanted

intramuscularly into the mouse hindlimb. To track the inflammation resulting from
transplantation, a dual-agent cellular MRI technique was developed. This technique utilizes
19

F to track MSC and superparamagnetic iron oxide nanoparticles (SPIO) to image

macrophages, through signal quenching. A clinical imaging protocol was developed to
translate

19

F-MRI to a 3T GE MR750 scanner with a dual

19

F/1H-tuned surface coil.

Peripheral blood mononuclear cells (PBMC) were labeled with a FDA-approved

19

F-agent

and injected into a ham shank phantom for protocol optimization. Results: The balanced
steady-state free precession pulse sequence was chosen for all studies due to the high signalto-noise per unit time.

Image acquisition was optimized for

19

F detection sensitivity,

accuracy of quantification, and compatibility with isoflurane. In vivo quantification of MSC
on the day of implantation was in strong agreement with the expected number of cells. The
change in

19

F-signal was quantified over time and compared between two murine

transplantation models. When iron oxide was administered i.v., the migration of immune
cells could be tracked to the injection site. The presence of SPIO decreased both the 1H and
19

F signal, indicating that transplant rejection was occurring. On a clinical system, as few as

4x106 PBMC could be imaged following both surface and subcutaneous injection. The
minimum number of detectable cells was strongly influenced by intracellular

19

F uptake.

Conclusions: 19F-MRI is a promising tool for imaging cellular therapeutics. By pre-labeling
cells of interest, they can be localized and the change in signal can be quantified over time.
The

technique

shows

promise

for

both
i

pre-clinical

and

clinical

applications.
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Chapter 1
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Introduction*

This thesis develops and advances magnetic resonance imaging (MRI) techniques for
non-invasive, in vivo tracking of cellular therapeutics. Research was performed with
imaging phantoms and animal models. This introductory chapter discusses cell therapy,
cellular imaging techniques, and cellular MRI to provide background and motivation for
the research presented in this thesis.

1.1 Cellular Therapy
Cell therapy involves the administration of healthy cells into a patient in order to treat a
disease or condition. Therapeutic cells from the patient can be specialized and expanded
in vitro, then re-administered to the most favourable location in the patient. Pre-clinical
experiments have shown that cellular therapy has the potential to revolutionize numerous
fields within modern medicine; with applications ranging from regenerative medicine to
immunotherapy.

1.1.1

Regenerative Medicine

Stem cell transplants are of particular interest for treating a variety of chronic disorders.
Defined by the cell potency, “true” stem cells are pluripotent allowing for differentiation
into any cell type. Multipotent stem cells, also known as progenitor cells, have the
potential to differentiate into multiple cell types, but are limited compared to pluripotent
cells. Mesenchymal stem cells (MSC) were first defined in 1991 by A.I. Caplan. to
denote the
___________________
*This chapter contains sections which have been previously published. Section 1.3.1, and
1.4 contain exerts from: Fox MS, Gaudet JM, and PJ Foster (2015) “Fluorine-19 MRI
contrast agents for cell tracking and lung imaging,” Magnetic Resonance Insights
8(S1):1-15. Copyright is held by the authors. Section 1.3, 1.3.2, and 1.3.3 contains exerts
from: Makela AV & Murrell DH, Parkins KM, Kara J, Gaudet JM and PJ Foster (2016)

2

“Cellular Imaging with MRI,” Topics in Magnetic Resonance Imaging 25(5): 177-186.
Sections are reproduced with permission (see Appendix A).

stromal progenitor and presumed stem cells for the skeletal tissues of bone, cartilage,
muscle and fat.1 First derived from bone marrow, MSCs are one of the most investigated
stem-like cells in clinical research. With applications in generating cardiac muscle,2,3
stroke recovery,4,5 and osteoarthritis repair;6 MSCs have the additional advantage of
being present in adult tissue. In addition to directly replacing damaged tissues, stem cells
have been shown to exert a local therapeutic effect through the release of trophic
factors.2,7,8 Studies have shown that under the right conditions MSCs can be induced to
pluripotency. However, recent work has shown that individual MSCs in culture are often
already pre-dispositioned to certain lineages, disputing the claim of true multipotency.7,9
This has led to extensive debate on “how potent” an individual cell must remain to be
considered a stem cell.7,9,10 Numerous groups have advocated for new definitions of
MSCs, differentiating multipotent stromal cells from bone marrow derived mesenchymal
stem cells.9,11,12 For simplicity, the term MSC as used in the remainder of this thesis
refers to the encompassing broad MSC definition, without attempting to differentiate
based upon the potency of the cells in culture.
Ultimately, the restorative effects of regenerative medicine relies on the arrival and
survival of the cells at the targeted destination. Stem cells can be administered either
systemically or at the therapeutic site.7 In either case, the cells must adapt to the local
environment following expansion and specification in culture. Studies have shown that
the majority of stem cells die in the days following transplantation.13–17 This may occur
from a number of factors, such as: shear stresses encountered with needle delivery or
insufficient access to nutrients. In either event, pro-inflammatory cytokines are released
by dying stem cells, which in sufficient quantities is capable of trigging an influx of
immune cells to the site of transplant.18,19
Transplant rejection is further mediated by differences in the genetic background of the
stem cells and host. This can occur as a rapid acute response from the recipient’s immune
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system towards the major histocompatibility complex (MHC) of the donated cells,18,19 or
a long-term chronic rejection involving loss of vascularity.19 Alternatively, in the case of
tissue transplants, donor immune cells present within the transplant may attack the host
tissue; a process known as graft-versus-host disease (GVHD). For human cellular
transplants, ideally stem cells are collected from the individual patient themselves,
preventing adaptive immune rejection and GVHD, producing an autologous transplant.
However, depending on the disease/condition and previous therapeutic treatments, these
autologous cells may not be suitable for administration.

Isografts are a near-ideal

alternative with donor cells produced by a genetically identical background, such as an
identical twin. Clinically, allograft transplantations are the most common, involving nongenetically identical donors. In these cases, immunosuppressive drugs are commonly
required to prevent transplant rejection. Recent work has suggested that MSCs may
display immune privileged properties, potentially allowing for unassisted allogeneic
donation.7,12,20 However the degree of immune suppression has been contested with many
reports suggesting it is insufficient to prevent allograft rejection.12,16
These models can be tested pre-clinically; with isografts produced by in-bred murine
strains and allografts using cells between murine strains. In addition, xenografts can be
investigated with donated cells from a different species as the host. This often results in
hyper-acute rejection of the transplants,21 although stable xenografts can be produced
with severely immune-compromised mice transplanted with human stem cells.

1.1.2

Immunotherapy

In the field of cancer immunotherapy, the patient’s immune system is primed to target the
tumour. This can be accomplished by introducing antigen-presenting cells (APCs) which
have been exposed to tumour antigen in vitro prior to administration. Once treatment has
been delivered to the patient, the APCs must migrate to a secondary lymphoid organ in
order to elicit an immune response. Here APCs interact with other cells of the adaptive
immune system, such as T-cells, which ultimately proceed to target the tumour.22–24
Unlike traditional prophylactic vaccines, these treatments are meant to be therapeutic
providing alternative treatment options.
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For many years, dendritic cells (DCs) have been investigated as the ideal APC for
application in immunotherapy. In vivo, DCs play a pivotal role in initiating the immune
response to foreign antigens. Capable of being derived from bone marrow or blood
monocytes; DCs are characterized as highly MHC II expressing, with the absence of
lineage

markers,

such

as:

CD14

(monocytes),

CD19

(B-cells),

and

CD68

(macrophages).25,26 Since the first DC clinical trial was reported in 1996 for B-cell
lymohoma,27 many patients have undergone vaccination trials for a range of cancers.
Unfortunately, clinical success of DC-therapy has been limited with the majority of trials
failing to show significant survivorship benefit.22,23,28,29 It is clear that additional research
is necessary to improve DC migratory efficiency and ensure immune tolerance is avoided
to improve clinical outcomes.28
On April 29, 2010, Sipuleucel-T, a cellular vaccine treatment was approved and licenced
by the US FDA for metastatic castrate-resistant prostate cancer (mCRPC). Although
localized prostate cancer has a good prognosis, there are currently few treatment options
following systemic spread. In multiple Phase III clinical trials, Sipuleucel-T has shown a
statistically significant survivor benefit over placebo controlled groups.24,30 Treatment
involves loading autologous peripheral blood mononuclear cells (PBMC) with an antigen
construct containing prostatic acid phosphatase (PAP) and granuocyte macrophage
colony-stimulating factor (GM-CSF). The PBMC fraction consists of a heterogeneous
mixture of cells, containing professional APCs, such as: DCs, monocytes, and B-cells;
along with activated: T- and NK cells. Following in vitro antigen loading of the PBMC,
the cells are administered intravenously back into the patient.31

While cancer

immunotherapy has only shown modest overall survival benefits in the clinic,
progression-free survival was not significantly improved.30,32 Coupled with the high cost
of treatment innovative approaches, such as those presented within this thesis, are
necessary to advance the clinical application of cancer immunotherapy.

1.2 Magnetic Resonance Imaging
The following sections are meant to provide a brief overview of the fundamental
processes involved with generating an MR image. Additional information can be found in
several textbooks, such as: “Magnetic Resonance Imaging: Physical Principles and
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Sequence Design, 2nd ed.” by Robert Brown et al.33 and “From Picture to Proton” by
McRobbie et al.34

1.2.1

Nuclear Magnetic Resonance

At the single voxel level, signal in MRI is derived from the dissipation of energy from
spinning nuclei within a magnetic field. All nuclei have a characteristic spin (I) value;
however only those with non-zero spins (I=1/2, 1, 3/2, …) produce a nuclear magnetic
resonance signal. In MRI, most nuclei of interest are spin ½. When a collection of spins
are placed within an external magnetic field (B0), these spins either align with or against
the applied field. Signal in MRI is governed by the small excess proportion of these
spins in the lowest energy state; or those in alignment with B0. The energy difference
between the two states is dependent on the strength of B0, as shown in Equation 1.
∆" =

%&'
(

(eq.1)

Where µ is the nuclei’s magnetic moment (discussed further in Table 1). As the
difference in energy level increases, a higher proportion of spins align with B0. At
thermal equilibrium, the ratio of spins in each population can be described with the
Boltzmann distribution (Eq. 2). Here, N+ and N- represent the number of spins in
alignment with or against B0 respectively, k is the Boltzmann constant, and T is the
temperature of the system. For this reason, imaging at higher field strengths (7T, 9.4T,
11.7T) improves signal compared to clinical magnets (1.5T, 3T).
)*

-∆.

)+

= , /0

(eq.2)

In addition to spin state, nuclei also present a characteristic precession about the main
magnetic field. Governed by the nuclei’s gyromagnetic ratio (g) and B0, the Larmor
frequency is given by Equation 3.
12 = 342

(eq.3)
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Table 1: Properties of relevant nuclei

Element

1

H

19

F

Gyromagnetic

Natural

Magnetic moment

Ratio (MHz/T)

Abundance (%)

(5/5N)

42.57

99.98

2.793

½

40.08

100

2.629

½

Nuclear Spin

Energy can be provided to excite the nuclei by applying a radiofrequency (RF) pulse at
the nuclei’s Larmour frequency. Following excitation, the net magnetization (M) returns
to the lowest energy state through the longitudinal (T1) and transverse (T2) relaxation
time constants. T1 relaxation involves the growth of magnetization (Fig 1A), along the
direction of the B0 field, defined as the z-axis. This occurs through the transfer of energy
from the excited nuclei to the lattice. T2 relaxation governs the exponential decay of
magnetization (Fig 1B) within the xy-plane through transfer of energy between spins
resulting in loss of phase coherence. The observed transverse relaxation rate (1/T2*) is
accelerated due to reversible dephasing because of: off resonance effects, molecular
mechanisms, and magnetic field inhomogeneities.

Figure 1: Graphs of Longitudinal and Transverse Relaxation rates. In both cases
the y-axis is normalized to M0, the magnetization of the sample induced by the main
magnetic field.
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1.2.2

Generating an Image

In MRI a magnetic field gradient along each Cartesian axis (x,y,z) is utilized to provide
spatial localization of voxels. These magnetic gradients are many orders of magnitude
smaller than the main magnetic field and are highly controlled. The application of a
gradient influences the precession frequency of the nuclei across the gradient, resulting in
a distribution of phases associated with the spatial location. Spatial information is
obtained by assigning a unique initial phase and frequency to each location. This
achieved by manipulating the duration and magnitude of these gradients across the field
of view.
The timed RF excitation and magnetic field manipulations are defined in the MR pulse
sequence. There are two categories of sequences, characterized by the method used to
generate transverse magnetization coherence. In a standard spin echo (SE) sequence,
spins are first excited by a 90° RF pulse. Magnetization is refocused (known as an echo)
some time later by applying a second RF pulse, which reverses the direction of the spins.
This reversal causes the spins to rephase and regain spin coherence at the echo time (TE).
Due to the second RF pulse, SE sequences refocus all reversible signal and have the
advantage of obtaining optimal signal per excitation, governed by T2.
The second type of sequence forms an echo through inverting the applied magnetic field
gradient. For gradient echo (GE) sequences, an initial RF pulse is again used to excite the
spins, although the flip angle is generally <90°. After excitation, the frequency encode
gradients are applied to enhance dephasing, then reversed in amplitude to form an echo at
TE. However, the resulting echo does not correct for field inhomogeneities, resulting in
the T2* reductions to signal. Despite obtaining lower signal per excitation, this is offset
by the capability to perform lower repetition times (TR) between excitations; which
allows for more signal averaging within the same time period.
In either case, the formation of an echo induces a current in the receive coil which is
translated into a digital signal and stored in an array matrix known as k-space. Data in kspace represent spatial frequencies, with each individual point containing frequency and
phase information on every voxel in the corresponding image. The center of k-space
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contains information on low frequencies, such as crude contrast and shapes; while high
frequency information is found in the periphery of k-space, providing the boundaries and
details. From here the data can be extracted from k-space and an MR image formed using
the Fourier transform. This acts to separate the signal into a sum of sine waves with
varying frequency, phase, and amplitude.
The signal intensities of an individual image voxel are governed by three factors: the spin
density, T1, and T2 values of the material being imaged. The spin density governs the
maximum potential magnetization (M0) providing the upper limit on the signal available
to be detected. Image contrast is also influenced by the choice of pulse sequence and can
be manipulated by adjusting the TR and TE of the sequence. For example, imaging with
a long TE allows material with a short T2 to relax reducing the observed signal.
Meanwhile, material with a longer T2 would appear brighter as more spins are rephased
to form the echo. The manipulating the TR has a similar effect on the images by varying
the magnetization excited into the xy plane.

1.2.3

Balanced Steady-State Free Precession

Balanced steady-state free precession (bSSFP) is an advanced GE pulse sequence, and is
also known by the vender specific names FIESTA, TrueFISP, and Balanced FFE. Unlike
with conventional sequences, magnetization is not allowed to completely return to Mo
prior to re-excitation. This generates a transverse and longitudinal magnetization steadystate after successive excitations. In addition, all gradient waveforms are also balanced to
a net value of zero in each TR, as shown below in Figure 2.
Due to the magnetization steady-state, contrast is dependent on the ratio between T2/T1.
The optimal flip angle is given by Equation 4, and results in the magnetization amplitude
given by Equation 5.35
:;
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(eq.4)

(eq.5)
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Figure 2: Balanced steady-state free precession pulse sequence diagram. The time to
form an echo (TE) is commonly set to ½ the repetition time (TR). In a single
sequence repetition all gradient magnitudes are balanced to produce a net of 0.
Figure adapted from “Picture to Proton”34
bSSFP has the advantage of generating high signal-per-unit time images. This is
accomplished by keeping TR extremely low (TR<<T1, often <10ms), which allows for
high signal averaging. However, this has the disadvantage of requiring strong gradient
slew rates and increased tissue heating, measured through specific absorption rate
(SAR).35
The pulse sequence displays a characteristic banding artifact. This occurs since the
transverse magnetization approaches zero at multiples of 2p. This can be offset by a
technique known as phase cycling, which varies the location of the dark bands allowing
for them to be removed through signal averaging.
The high signal advantages and unique contrast generated by bSSFP have been utilized
for real-time cardiac imaging,35 angiography,35 oncology,36 and cellular MRI.37,38 The
lack of T2* dependence on signal is particularly useful for controlling the size of the
blooming artifact produced by superparamagnetic iron oxide (SPIO) nanoparticles.
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1.2.4

Iron Oxide-Contrast Agents

In MRI, regions of interest (ROIs) can be emphasized using paramagnetic and
superparamagnetic agents which influence the image contrast.

Localized positive

enhancements to the signal can be achieved with gadolinium or manganese agents, while
negative contrast can be generated with iron oxide agents. When imaged with a MRI,
SPIO particles result in a reduction in the local T1, T2, and T2*. This is caused by
disturbing the local magnetic susceptibility and is most pronounced in the immediate
vicinity of the superparamagnetic material. With conventional sequences, the T2 and T2*
reductions appear as a region of negative contrast on the image. The size of this region is
dependent on a number of factors, such as: the pulse sequence timing, method of echo
formation, and field strength;39 with the largest effects visible in T2*-weighted images.33
Positive image contrast is possible with certain advanced methods such as: ultrashort
echo time (UTE) imaging, with the echo formed in less than the T2*;40 or through
inversion recovery with on-resonance water suppression.41

1.3 Imaging Cellular Therapeutics
While pre-clinical experiments have shown that cellular therapy can be successful,
despite decades of research, cellular therapy has been unable to meet clinical
expectations. One problem exists in that once these cells are re-administered to the
patient it often takes months before diagnostic feedback is available. In this time, it is
unknown if the cells are providing any therapeutic benefit to the patient.
Cellular imaging aims to shed light on the in vivo fate of these therapeutic cells. By
directly and non-invasively imaging these cells, imaging provides a window through
which we can confirm correct administration, observe migration, and evaluate
longitudinal status of the cells. In the pre-clinical setting, imaging allows for more rapid
treatment optimization in animal models, as data can be obtained throughout therapy
instead of just at the endpoint. In the clinic, imaging presents an avenue to evaluate the
success of therapy at multiple time points, often before symptomatic indicators are
available. This provides the capability to verify both the success of delivery and evaluate
treatment progression, providing the capability to intervene if necessary.
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There are currently several established in vivo cell-tracking methods including: optical
(fluorescence microscopy & bioluminescence imaging [BLI]), radioactive tracers
(positron emission tomography [PET] & single-photon emission computed tomography
[SPECT]), and MRI using heavy metal contrast agents (superparamagnetic iron oxide
[SPIO] & paramagnetic gadolinium [Gd]). Each of these modalities has their respective
advantages and disadvantages. For example, BLI signal is semi-quantitative and only
produced by living cells, but is attenuated with tissue depth and requires non-native
transfected cells.42,43

By comparison, PET is highly sensitive at all depths and is

clinically translatable, but the ionizing radiation can be highly toxic to sensitive
therapeutic cells.44

In addition to these methods, there are two recently developed

technologies, magnetic particle imaging (MPI)45 and fluorine-MRI (19F-MRI).46 The
relative differences between some of the more common techniques are compared in Table
2. The values presented are approximate guidelines of each technique; with values being
highly dependent on imaging time, protocol and equipment.

1.3.1

Cellular MRI

In comparison to other cell imaging techniques, cellular MRI has the advantage of being
clinically translatable without exposure to ionizing radiation. The anatomical images
provide excellent spatial resolution and soft tissue contrast. Most cellular MRI to date
has been performed with SPIO. Cell tracking with iron oxide was first utilized by Bulte et
al. and Yeh et al. in the early 1990s by internalizing iron oxide particles within cells and
detecting the resulting negative signal contrast.47–49 The disruption of the local magnetic
field can be used to determine the spatial localization of iron oxide. In T2-weighted
images this provides cell spatial localization near that of the proton image resolution. The
resulting signal void occupies a much larger spatial region than the individual cells
themselves preventing the need for magnification. As previously discussed in Section
1.2.4 and in Table 2, small quantities of label can have large detectable effects on the
magnetization of the surrounding spins. This has led to extremely high detection
sensitivity, with single cell detection possible under certain conditions.37,50 However,
since detection of the agent relies on a change in image contrast, localization of the iron
oxide is limited by low specificity. Dark regions with low proton density, such as the
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bone and lung, can appear similar to iron oxide signal void. In addition, in vivo
quantification of iron containing cells is complex. The fractional signal loss produced by
SPIO is only linear at very low concentrations of iron oxide, and quickly reaches a
saturation point after which further signal loss does not occur.37 This makes it extremely
difficult to quantify the amount of iron present within a signal void. Nevertheless, over
the years SPIO have been used to track a vast range of cells, such as: immune cells,44,51–54
stem cells,55–57 cancer cells,58–60 and pancreatic islets.61

1.3.2

Labeling Therapeutic Cells for MRI

Cells of interest must first be labeled with an imaging agent allowing for their specific
detection. These agents can be genetically engineered into the cells,68 administered to the
cells in culture prior to administration,69 or injected intravenously to label native cells in
situ.14 For imaging cellular therapeutics with MRI, the most common method employed
to label cells is in vitro. This provides the greatest control of label uptake, ensuring only
the specific cells of interest are labeled.
In general, there are three classes of iron oxide agents used in imaging: 1) ultra-small
superparamagnetic iron oxide nanoparticles (USPIO) [5-50nm], 2) superparamagnetic
iron oxide nanoparticles (SPIO) [50-150nm], and 3) micron-sized iron oxide particles
(MPIO) [1µm]. A single MPIO particle contains >5pg/Fe, an amount equivalent to 1.5
million SPIOs or 4.3 million USPIOs.70 The iron oxide core is often surrounded by a
dextran coat to prevent aggregation and enhance biocompatability.71 Although there are
no FDA approved iron oxide cell imaging agents, one agent is currently being
investigated for off-label use. Ferumoxytol is an I.V. administered USPIO-sized agent
used to treat iron-deficiency. Many cell types are capable of taking up nanoparticle-sized
agents without intervention, and these cells can be labeled to sufficient levels for imaging
(>1pg/Fe per cell) by simple co-incubation. This is particularly important when
considering clinical feasibility, since transfection agents are not required. Cells mediate

Table 2: Comparison of common cell tracking techniques
MRI - Iron oxide

Sensitivity

1-10 cells
(0.01ng/voxel)37

MRI - 19F

PET - 18F62,63

SPECT - 111In64,65

MPI - Iron oxide45,66

BLI -luciferase42,67

10,000 cells (300ng/voxel)

100-1000 cells

100-1000 cells

100 cells (5ng/voxel)

1000 cells

Cellular loading

>99% (1-10pg/cell)37

>99% (0.3-30pg19F/cell)

4-99%

4-25% (diluted)

>99% (1-25pg/cell)

>95%

Resolution

µm

mm

mm

mm

mm

mm

Bystander labeling

Yes

Yes

Yes

Yes

Yes

No

Quantifiable

Semi

Yes

Yes

Yes

Yes

Semi

Imaging Time

Minutes

Minutes

Seconds

Seconds

Seconds

Seconds

Longitudinal potential

Months

Months

Hours

Days

Months

Months

Total Imaging Cost

$$$

$$$$

$$$

$$$

$

$

Clinical translatability

Under evaluation

Under evaluation

Approved

Approved

No

No

14

nanoparticle uptake through a variety of endocytosis pathways; including: phagocytosis,
clathrin-, and caveolin-mediated endocytosis.41,72 The preferred method is dependent on
cell type, as well as the size and surface coating of the agent. Following internalization,
the nanoparticles are contained within vesicles in the cytoplasm. Higher label-uptake is
possible with phagocytic cells, which are capable of taking up additional label through
phagocytosis.72 Following label internalization, it is also important to ensure that these
agents do not induce functional or phenotypic changes in the cells that they label.
Numerous studies have shown that labeling MSCs does not impact short- or long-term
viability, proliferation, or differentiation into adipogenic or osteogenic lineages.56,73
However, Rohani et al. demonstrated differences in activation and migration of DCs
labeled with micron-sized iron oxide particles.51

1.3.3

Imaging Inflammation

Besides labeling cells in culture, phagocytic cells can also be labeled in situ following
intravenous (i.v.) administration of an imaging agent. This is particularly useful for
tracking localized inflammation, through the large influx of immune cells. In mice, the
cellular imaging agent is administered through the tail vein with imaging performed 24
hours later. Most of the agent is cleared from the blood through the mononuclear
phagocytic system, resulting in uptake by; Kupffer cells in the liver, monocytes in the
bone marrow, and macrophages in the lymph nodes and spleen. Applications have been
shown in a variety of fields, such as: myocardial infarct,74,75 stroke,76

transplant

rejection,13,14,53,77 tumour-associated macrophages,78,79 and spinal cord injury.80

1.4

19

F-MRI Cell Tracking

The first 19F observations were attempted with NMR in 1942,81 followed by MRI in the
1970s.82 Since then, 19F imaging agents have been used for a variety of purposes, such as
to measure the intracellular partial pressure of oxygen83 and as a gastrointestinal contrast
agent by proton displacement.84 Nuclear magnetic resonance signal from

19

F has been

used to investigate lung structure and drug pharmokinetics. Unlike with iron oxide
agents, nuclear magnetic resonance signal from the

19

F atoms are directly detected and

there is no disruption to the underlying proton image contrast. Once the detection
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threshold has been reached, the signal produced is linearly proportional to the number of
19

F atoms, allowing for quantification;85 details of which are expanded upon later in

Chapter 2. A drawback of this direct detection is the relative insensitivity of the nuclear
magnetic resonance signal. As discussed in Section 1.2.1, signal in MRI is governed by
the surplus of spins in alignment with the main magnetic field. With standard MRI this is
not a concern, due to the high abundance of 1H in biological tissue. For 19F-MRI, a large
number of additional 19F atoms must be introduced to the cell in order to produce enough
NMR signal to be detectable. This requires mM concentrations (~ 1015
voxel for imaging.

86

19

F atoms) per

19

However, due to the near-absence of native F-atoms in biological

tissue no background signal is observed, providing excellent imaging specificity.
The first application of 19F-MRI for cell tracking was demonstrated in 2005 by Ahrens et
al.46 In this study, immunotherapeutic DCs were tracked following subcutaneous
injection to the draining popliteal lymph node.46 Cells were labeled in vitro by coincubation with an emulsified perflurocarbon (PFC), which was internalized through
phagocytosis. Anatomical localization was achieved by overlaying the

19

F image onto a

traditional proton MR image. In the 11 years since this first study, the field has grown at
an exponential rate,87 with significant advances in hardware,88–90 image acquisition,56,91,92
and data processing.93,94 To date, most of this work has been performed at high-field
strengths (>7 T), to improve sensitivity of 19F-MRI. Studies have demonstrated 19F can be
added to cells in culture and used to track stem cells from hematopoietic,95 neuronal,96
and mesenchymal progenitors;56 as well as a variety of immune cells, such as: DCs,46,97,98
NK cells,99 T-cells,100 and macrophages.77 PFC uptake has been observed in both T- and
B-cells, which have been historically difficult to label with SPIO-based agents.100
Dendritic cells have been by far the most frequently imaged cell type with

19

F-MRI.

Besides the natural phagocytic ability allowing for high intracellular label uptake in the
range of 1012

19

F atoms/ cell; DC do not undergo mitotic cell division preventing the

diffusion of label. Finally, the known migratory pathway to the draining lymph nodes
provides the perfect translation model for assessing in vivo functionality with imaging.
Building on previous work by Dr. Ahrens, in 2010 Helfer et al. introduced the first
commercial 19F imaging agent by imaging the migration of DCs to the draining popliteal
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lymph node.97 In this study, extensive work was performed to show that labeling did not
negatively affect the expression of surface markers, DC maturation, and T-cell
stimulatory function.97 In 2011, a German group led by Dr. Waiczies showed that the
labeling efficiency of DCs increased with the PFC particle size, up to a maximum of
560nm diameter.101 Interestingly, their work showed improved T-cell activation
following

19

F-loading of DCs;101 suggesting heavy intracellular

19

F-uptake may act to

induce DC maturation processes. With these promising results, the clinical feasibility of
detecting DCs in vivo was first explored in 2011 by Bonetto et al.102 In this work, they
showed an intracellular uptake of 1.7x1013
efficiency to date.

102

19

F/cell, the highest reported labeling

Using a spin density weighted SE sequence on a 7T system, a

minimum of 2000 cells/voxel could be detected in phantoms.102 These results were
extrapolated to provide an estimation of a minimum detection threshold of 30,000
cells/voxel on a clinical 3T MRI,102 or around 5x1017 19F atoms.
Another common application of 19F-MRI has been for imaging stem cell transplants. The
field is well suited to

19

F-MRI, since large numbers of stem cells are routinely

administered in translational models. Like with DCs, PFCs have been shown to not
negatively influence stem cell surface markers, differentiation, or proliferation.56,103
Using relatively simple transplantation models has allowed for groups to test and
optimize more advanced 19F techniques. An example of this is in 2007, Partlow et al.
demonstrated that two-colour 19F-MRI could be used to distinguish separate populations
of stem cells that had been labeled with different PFC agents.95 By selectively exciting
each agent individually, the different cell populations could be imaged in sequential

19

F

scans.
Immune cells can also be labeled in situ by i.v. administration of PFC, in the same way as
described in Section 1.3.3. However, with 19F-MRI this allows for both the inflammatory
sites to be both spatially localized and the relative level of inflammation to be
compared.74,75,104–107 In addition to the quantification potential, imaging inflammation
with 19F-MRI produces few anatomical image distortions compared to iron oxide. This is
particularly advantageous when imaging arthritic inflammation around joints, where the
negative iron contrast can be easily confused with the low proton density bone. In a study
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by Balducci et al.,

19

F-MRI was used to assess longitudinal responses to an arthritis

therapy.108 Inflammation as marked by 19F-signal was observed to increase in untreated
controls, but

19

F-signal remained constant in prednisolone treated animals.108

Unfortunately no 19F clearance was observed overtime, despite the success of therapy as
measured by other clinical responses.108 This highlights one of the drawbacks of using
cellular MRI for longitudinal inflammatory imaging, macrophages are known to remain
in the tissue for an extended period of time after the initial inflammation subsides. In
addition to imaging inflammation near bone, cardiac tissue is another region where joint
1

H/19F MRI has an advantage over previous techniques. In 2008, Flogel et al. imaged

inflammation following cardiac ischemia, showing a time dependence on the observed
19

F-signal between 1 and 6 days post ischemic event.75 This differed from results

observed in a similar model using SPIO, where no difference in fractional signal loss was
observed after 24 hours.13 This is likely due to the saturation of the signal loss that occurs
with iron-oxide, and highlights the advantage of using 19F-MRI for quantitative analysis.
19

F MRI has also been utilized to image acute allograft rejection following heart

transplantation in mice.107 Inflammation could be differentiated and quantified between
the left and right ventricles of the heart,107 potential allowing for targeted interventions to
be performed to prevent the organ from being rejected.

1.4.1

Perflurocarbon Imaging Agents

Due to the toxicity of ionic

19

F atoms, imaging is predominately performed with

biologically inert PFC. These agents make use of the carbon-fluorine bond, the second
strongest bond in organic chemistry, which cannot be naturally broken.109 This produces
biologically safe, inert agents for imaging. In the 80’s, PFCs were evaluated as a blood
substitute option in patients due to the high affinity for O2.110 In comparison, for cell
tracking applications only minuet quantities of PFC are used, with clearance through the
monocyte-phagocyte system and lung exhalation.111,112
PFCs are generally produced by replacing hydrogen atoms on hydrocarbon chains and
can be designed to be linear (perfluoropolyether [PFPE]) or cyclic (perfluoro-15-crown5-ether [PFCE]). In either case, the ideal imaging agent possesses a high number of 19F
atoms with a single resonant peak and a short T1 allowing for rapid imaging. Table 3 lists

18

relaxation times at a variety of field strengths for commonly used

19

F agents in cell

tracking.
Table 3: PFC relaxation rates vary with agent and field strength

Agent

PFPE

Single

# 19F

Peak

Spins

No

28-36

T1 (ms)

T2 (ms)

3T: 470112

3T: 250112

7T: 590,113 425114

7T: 82114

9.4T: 510113
11.7T: 280,115 380115
7T: 2500,113 950100
98

PFCE

Yes

20

93

9.4T: 580, 600,
116

1000

11.7T: 800

97

11.7T: 153,115 68115

7T: 50100
9.4T: 536,98 300,93
350116

At the moment there is only a single commercial PFC designed for cell tracking. Based
on a PFPE backbone, Cell Sense (CS-1000, CelSense Inc.) is produced under the Good
Manufacturing Practices (GMP) required for clinical applications. As such it is the only
commercially available, FDA-approved cellular MRI agent. For pre-clinical work, the
agent is available in fluorescently tagged variants (CS-1000 DM-red), as well as in a
form suitable for IV injection for in situ labeling of phagocytes (VS-1000).

1.5 Purpose of Thesis
Since 2005, numerous proof-of-concept studies have been performed with a variety of
cell types in various disease models.

However, until recently, this work has been

restricted to a handful of laboratories with the necessary combination of expertise and
equipment. The purpose of this thesis was to develop technology and implement the first
19

F-imaging site in Canada, capable of both pre-clinical and clinical cell tracking.

19

1.5.1

Hypotheses
1. Transplanted cell number and spatial location can be non-invasively
monitored with longitudinal 19F-MRI.
2. Differences in stem cell fate can be detected between isograft and xenograft
transplantation models with 19F-MRI.
3. The combination of 19F-labeled stem cells and iron-labeled immune cells will
allow for simultaneous MRI446 of transplant rejection.
4. Clinical cell tracking will be feasible with 19F-MRI for a future cancer
immunotherapy clinical trial.

In Chapter 2, the development and implementation of small animal

19

F-MRI is outlined

for a 9.4T MRI system. This work introduces and provides additional details for the preclinical imaging protocols utilized by this thesis.
In Chapter 3, the stem cell fate in two models of murine transplantation were investigated
with 19F-MRI. Validated with histology, this work shows that 19F-MRI is a powerful tool
for non-invasive, longitudinal imaging. This chapter was published in PLoS ONE
(Gaudet et al. Tracking the fate of stem cell implants with fluorine-19 MRI. PLoS ONE.
2015 10(3):e0118544)
In Chapter 4, the natural immune response to a rejected transplant was imaged with dual
cellular MRI agents. Immune cells were tracked following in situ labeling with iron
oxide, while stem cells were monitored with 19F-MRI. This chapter was published in the
journal, Magnetic Resonance in Medicine (Gaudet et al. Application of dual 19F and iron
cellular MRI agents to track the infiltration of immune cells to the site of a rejected stem
cell transplant. MRM. 2016)
In Chapter 5, a 19F-cell tracking imaging protocol was developed for an upcoming phase
1 clinical trial. This trial will involve the administration of APCs intradermally into the
upper thigh of prostate cancer patients. Imaging was validated at 3T with a porcine tissue
phantom. Sections of this chapter are under review at PLoS ONE (Fink et al.

19

F-

perfluorocarbon-labeled human peripheral blood mononuclear cells can be detected in
vivo using clinical MRI parameters in a therapeutic cell setting.)

20
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Chapter 2

2

Optimization of Preclinical 19F-imaging Techniques

As the first 19F-MRI cell tracking site in Canada, a number of parameters and protocols
required development and optimization prior to beginning animal studies. This chapter
provides additional details on the methods utilized in the following chapters for

19

F

acquisition, with a focus on minimum detection limit and quantification accuracy.

2.1 Equipment
Pre-clinical imaging was performed on a 9.4T Varian/Agilent small animal scanner. The
high-field system provides a number of advantages for

19

F detection. As discussed in

Chapter 1, net magnetization increases with the field strength, so a 9.4T system provides
more than 6x the signal of a clinical 1.5T MRI. In addition, the smaller bore size
provides more accurate shimming and allows for stronger gradient slew rates at small
animal sizes. All of these factors contribute to higher resolution and improved image
quality in murine images compared to a clinical MRI system. A

19

F/1H dual-tuned

birdcage volume coil, tuned to 376. MHz and 400.2MHz respectively, was produced in
house by Kyle Gilbert. The volume coil has a 2.2cm diameter and 5.1 cm length, and is
shown in Figure 3A, alongside the B1 map (Fig 3B). The relatively uniform B1 field at
the center of the coil provides more accurate cell quantification, further discussed in
Section 2.3. Coil diameter was kept as small as possible for murine imaging to optimize
sensitivity.

2.2 MRI Acquisition Parameters
2.2.1

Pulse Sequence

Overall, the vast majority of 19F-MRI studies have employed spin echo sequences.1 As of
2012, only a single study had utilized bSSFP for

19

F-cell tracking of pre-labeled cells.2

Since then, the high signal-per-unit time advantage bSSFP provides has been used in
numerous studies to investigate 19F-labeled MSC,3 NK cells,4 stromal vascular fraction

34

Figure 3: (A) Image of the dual tuned birdcage volume coil. The tuning frequency is
controlled by driving through one of the two coaxial cable connectors. (B) The
Actual Flip angle Image (AFI) shows the field uniformity in the center of the 19F
birdcage coil, with each circle representing a 5mm axial slice. The scale on the right
indicates the actual flip angle applied to the same following application of a 90o
pulse.
cells,5 and inflammatory cells.6

Expanding on Section 1.3.3, bSSFP has additional

advantages for multi-nuclear imaging compared to conventional sequences.7,8 The short
imaging repetition time (around 4ms) allows for 100s of imaging averages to be
performed in a reasonable scan time.

The high SNR produced improves detection

sensitivity, but can also be traded off to allow for higher resolution, an advantage that is
outlined in more detail in Section 2.2.2. When TR= 2*TE bSSFP images are not
influenced by T2*, despite being formed by a gradient echo-like sequence. This is an
important factor when considering quantification accuracy, since it relies on the
assumption that image contrast is constant across the image.9,10 Finally, PFC agents tend
to have relatively similar T1 and T2 values, providing the optimum steady state
magnetization as given by Equation 4.1,10 All of these factors, as well as the extensive
literature on iron cell tracking with bSSFP,11–15 influenced our decision to use the bSSFP
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sequence for this thesis. To date SSFP-based pulse sequences have shown the best

19

F

sensitivity, with only ultra-short echo time (UTE)-SSFP producing higher signal then
bSSFP.8

2.2.2

19

F Image Resolution

In general, SNR is expected to increase with larger voxel size. This is due to the fact that
with conventional proton imaging, larger voxels contain more hydrogen nuclei,
generating higher signal. However, with

19

F-MRI cell tracking, larger voxels do not

always lead to an increased SNR. This is predominately due to the fact that voxel size is
already orders of magnitude larger than the area taken up by the injected cells in vivo. In
this case, an increase in voxel size does not result in improved signal, since there are no
additional 19F nuclei to excite in the surrounding area. Instead, when field of view is kept
constant, larger voxels tend to decrease SNR due to increased under-sampling artifact.
An example of this is shown in Figure 4, where detection of 20,000 cells in 2mm3 voxels
(Fig 4A) is compared to 12mm3 (Fig 4B). Overall though, voxel size does need to remain
large compared to proton imaging to maintain sufficient 19F atoms/voxel.

Figure 4: Cell pellets containing 20,000 (white arrow) and 60,000 (yellow arrow)
cells. (A) SNR and image quality is higher, and quantification was found to be more
accurate at 2mm3 resolution, compared to (B) 12mm3 voxels.
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2.3 Quantification of Labeled Cells
2.3.1

Theory

Since signal produced by nuclear magnetic resonance is dependent on the number of
nuclei per voxel, it is inherently quantitative. Non-invasive, in vivo quantification of 19Flabeled cells was first described in 2010, by Srinivas et al.16 The basic procedure is
outlined in Figure 5. The first step towards quantification involves determining the
intracellular

19

F uptake, or mean fluorine content per cell (Fc). Following in vitro

19

F-

labeling of the cells, a sample containing a known number of cells is set aside for NMR
analysis (process 1). Samples were analyzed at the University of Western Ontario
Chemistry NMR facility with a Mercury VS 400MHz vertical bore magnet. Prior to
spectroscopy, the NMR cell sample is suspended in D2O and combined with 100µL of
0.1% trifluoracetic acid (TFA). Each TFA molecule has three identical fluorine atoms,
producing a single NMR spectrum peak at -76ppm. Using this information, Fc can be
determined by comparing the ratios of the NMR peak integral between TFA and the cell
sample. This calculation is shown in Equations 6-8.
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(eq.7)
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The second process determines the number of 19F atoms present at the region of interest
within the animal.

Imaging is performed alongside a reference tube of known

concentration containing the same 19F Cell Sense agent. By comparing the signal ratios of
these two locations, the number of 19F atoms at the ROI can be determined, as shown in
Equation 8.

Figure 5: In vivo quantification
can be performed when labeling
cells in culture prior to their
administration. Cells are
labeled through co-incubation
with a 19F-agent overnight to
allow for 19F-spins to become
internalized within cells.
Labeled cells are then split into
two separate pellets. The first
pellet undergoes process 1,
where NMR is used to
determine the mean
19

intracellular F uptake. The second pellet is administered into the host, either a pre-clinical model or a patient. Process 2
involves conventional 1H imaging of the host to provide the high resolution anatomical images. Then without moving the
patient, 19F imaging is performed over the same field of view in process 3. These two images can be overlaid for anatomical
context of the 19F signal. An external reference tube of known concentration is imaged alongside the host allowing for the
signal from the labeled cells to be converted to number of 19F atoms. By combining this information with the NMR data, the
number of cells can be quantified
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Finally, by combining Equations 7 and 8 it is possible to determine the number of labeled
cells present at the ROI, Equation 9.
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Improving Quantification Accuracy

Calculations were performed using Voxeltracker software provided by CelSense Inc.17
This imaging software simplifies the process by measuring signal and volume from handdrawn ROIs and provides an estimation of quantification error from the image noise.
Initially, quantification accuracy was poor, displayed in Figure 6 as the error multiple
from the expected number of cells on a log-scale. The software automatically applies a
Rician noise correction to improve accuracy.

Unfortunately, this noise correction

assumes the minimum noise distribution starts at 0. This assumption is often incorrect as
all voxels were found to contain some noise signal, as shown in Figure 6B.

By

subtracting a constant signal value (x) from all voxels, the distribution can be left shifted
back to the origin (Fig 6C). This step significantly improved quantification accuracy
between unadjusted (Voxeltracker) and subtracted data sets, as shown by Figure 6C.
Simplifying the data set by converting to 8-bit was also investigated, which inadvertently
left-shifted some datasets improving accuracy. However, information lost by restricting
to 256 bins hindered the robustness of the technique.
Further improvements were made to NMR accuracy by lysing cells to release the

19

F

agent prior to NMR. Without lysis, cells would sediment towards the bottom of the
NMR tube, resulting in a non-uniform suspension and reducing the accuracy of the
measurement.
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Figure 6: (A) Quantification error from six experiments is expressed as an error
multiple from the true value of 1 on a logarithmic graph. The black bars indicate
quantification error from raw un-adjusted data sets. (B) An image histogram of this
data reveals that all voxels contain some signal value, an assumption that is not
taken into account by the quantification software. (C) Improved quantification
accuracy is obtained by left-shifting the histogram by subtracting a fixed value,
equal to that of the lowest signal voxel, from all voxels as shown in the red bars.
Besides the methods described, 19F-MRI quantification has been demonstrated numerous
times in the literature with custom MATLAB scripts allowing for improved noise
corrections and automated thresholding.6,18–22 Extensive work has also been performed
with MR spectroscopy to improve the accuracy and sensitivity of quantification, at the
cost of image resolution.23–27
Ultimately, a number of factors contribute to quantification error.

These include

acquisition specific, such as: T1 and T2 differences between intracellular label and
external reference tubes, error in power calibration due to the lower 19F signal, Bo/B1 field
inhomogeneities; and at the cellular level, such as: uncertainty in cell number for NMR,
inaccuracy in injection number, and distribution of label uptake. For longitudinal
imaging, bystander labeling of native, non-targeted phagocytic cells provides the largest
source of error, which is explored in more detail in chapters 3 and 4.
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2.4

19

F-Uptake

The labeling efficiency, or amount of 19F per cell, is extremely important in determining
the minimum number of detectable cells due to the fact that NMR signal is directly
related to the number of nuclei within the voxel. For example, 10,000 cells containing
1x1012 19F atoms/cell produces the same signal as 1,000,000 cells containing 1x1010 19F
atoms/cell. We observed intracellular uptake to be highly variable amongst cell batches,
even in the controlled in vitro environment. The labeling variability is over orders of
magnitude, as highlighted in Figure 7A, with each point indicating an experiment
repetition. Uptake is influenced by the cell type, cell size, phagocytic potential, and
donor health, as well as the physical and chemical properties of the 19F agent itself. The
Cell Sense (CS-1000) incubation concentration also influences the labeling efficiency
(Fig 7B), but results in a decrease in viability at higher concentrations.

Figure 7: (A) Number of mean 19F atoms per cell as measured by NMR was
observed to vary by over two orders of magnitude within cell samples. Each data
point represents cells prepared for a unique experiment. We found cells from older
subjects tended to label less efficiently, in comparison to cells from younger subjects
and culture. (B) Incubation concentration of the 19F-agent Cell Sense also influenced
cellular uptake. However, at 7.5mg the cell viability was observed to decrease (data
not shown).
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2.5 Anesthesia
In order to reduce animal motion and stress most pre-clinical imaging relies on
anesthetized animals. Isoflurane is the most common veterinary anesthesia in use, due to:
the high tolerance, ease of administration through inhalation, flexibility of dosage, and
availability. However, due to the presence of
unwanted

19

19

F atoms, this anesthetic can produce

F-MRI signal3,28 unless appropriate precautions are taken. Figure 8 presents

the chemical structure of isoflurane alongside the

19

F NMR spectrum from an

anesthetized animal containing Cell Sense labeled cells.

Figure 8: Each isoflurane molecule contains five 19F atoms (A). They are visible in
the in vivo 19F spectrum of an anesthetized mouse (B, yellow arrow). Here the main
CS-1000 peak is visible centered at 0 Hz (white arrow) [-91.5ppm], along with two
isoflurane peaks [-86ppm and -81ppm].
In vivo, isoflurane accumulates in fat with a fat/blood ratio of 45.29 This is visible in 19FMRI images of a mouse (Fig 9A), imaged alongside a reference tube containing Cell
Sense. Imaging was performed centered at the Cell Sense frequency, resulting in a
spatial shift in the isoflurane signal from the fat pad. Here the default truncated sinc
excitation pulse was used (Fig 9B). Excitation of the isoflurane signal can be prevented
with a longer, un-truncated sinc pulse (Fig 9C&D). Following fourier transform; the
longer sinc pulse translates into a narrower rectangular excitation band in frequency
space. When centered on the Cell Sense frequency, this band is narrow enough to not
excite the nearby isoflurane peaks. We used this approach for all of our animal imaging.
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Figure 9: (A) Isoflurane signal (red arrow) is visible within the body of the mouse.
This signal is spatially offset from its true location in the fat pad (blue arrow) due to
the center frequency being locked on Cell Sense. (B) The default truncated sinc
pulse is narrower in temporal space then the sinc pulse (D). After fourier transform
the wider sinc pulse produces a narrower rectangular shape in frequency space,
preventing the excitation of isoflurane (C).

2.6 Two-colour 19F-MRI
Building on the same principle as avoiding isoflurane excitation, distinct 19F peaks can be
selectively excited in sequential acquisitions to provide two-colour 19F-MRI. First shown
in 2007 by Partlow et al., stem cells were labeled with either a PFOB or PFCE based
nanoparticle.2 This method allows for distinct cell populations to be identified and has
applications in tracking multiple systems simultaneously. In Figure 10, data from a pilot
experiment shows the i.v. distribution of Cell Sense (red) mapped alongside the
isoflurane distribution (green). It was particularly interesting to note that this data shows
that both Cell Sense and isoflurane are present in the liver. Although two-colour MRI
was not utilized in this thesis, the technique has strong potential for application in the
future directions of this work.
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Figure 10: By employing the narrow peak selective pulses, the distribution of i.v.
Cell Sense (red) can be imaged separately from isoflurane (green). The two 19F
images were then combined with an anatomical image.

2.7 Common Artifacts
The most common artifact observed in 19F-MRI cell tracking is the point spread function
(PSF) resulting from under sampled imaging. The artifact is especially prominent in 19Fcell tracking due to the strong signal produced by a point source of cells, and the lack of
background. PSF results in characteristic linear lines of noise in all three dimensions
centered on the point source, as shown in Figure 11.
This artifact can be reduced by increasing acquisition matrix size. However, due to the
relatively low number of 19F atoms located within each voxel, as well as the importance
of detecting all of these atoms for accurate quantification, lower resolution is preferable
for

19

F imaging (on the order of mm3 for pre-clinical systems). In order to keep voxel

size large enough for detection, the field of view can be increased to extend beyond the
animal. Unfortunately, this results in an increase of “dead-space” imaging, where no
animal is present, along with the increase in imaging time associated with a larger
acquisition matrix. The work presented in this thesis has attempted to balance acceptable
PSF image artifact with reasonable scan time.
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Figure 11: Point spread function artifact produced by a region of high intensity
signal. The artifact complicates image analysis, particularly when comparing signal
between structures in the opposite side of the animal.
Chemical shift artifacts are the second most commonly observed in images. This artifact
appears as a 1-2 voxel shift in spatial location between matched proton and fluorine
images. These occur when the 19F imaging frequency is offset from the Cell Sense peak
frequency, as shown with the isoflurane signal in Figure 8. Luckily, post-processing
correction of the artifact is simple by aligning the reference tubes in the

19

F and 1H

images.
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Chapter 3

3

Tracking the Fate of Stem cell Implants with Fluorine-19
MRI†

3.1 Introduction
Stem cell therapy has the potential to play an important role in regenerative medicine.
Mesenchymal stromal/stem cells (MSCs) have been extensively investigated for clinical
application over the past decade.1,2 MSCs are capable of differentiating into a variety of
important tissues, such as: bone, cartilage and adipose.3 They also display
immunomodulatory properties.4–6 Their presence in adult tissue, and ease of expansion in
vitro has made MSCs good candidate cells for clinical translation.7,8
To advance stem cell therapy, there is a desire to develop tools to monitor the survival of
implanted stem cells non-invasively after administration to the patient.

Magnetic

resonance imaging (MRI) cell tracking is an effective method to visualize and monitor
cells non-invasively after implantation due to the high spatial resolution and lack of
ionizing radiation.
The majority of MRI cell tracking studies have used iron oxide nanoparticles to label the
cells of interest.9–15 When imaged with MRI, the iron nanoparticles produce a dark signal
void in T2 and T2* weighted proton images.
permitting the imaging of single cells.

16,17

This technique is highly sensitive,

Limitations with tracking iron-labeled cells

arise from low specificity, due to other regions in the image with low signal, and from
complicated in vivo quantification of the signal loss. Our group and others have shown
that the degree of signal loss produced by iron labeled cells is only linear at low iron
concentrations.16,18 Furthermore the high sensitivity to iron can produce ambiguity due to
___________________
†

This chapter was previously published and is included here with permission and minor
revisions: Gaudet JM, Ribot EJ, Chen Y, Gilbert KM, and PJ Foster (2015)
“Mesenchymal stem cell transplant rejection monitored with 19F-MRI,” PLoS ONE 10(3):
e0118544.
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the strong false-positive signal produced when even a small number of bystander cells
become labeled inadvertantly.19,20
As an alternative to iron-oxide cell tracking, fluorine-19 (19F) MRI with perfluorocarbon
(PFC) nanoemulsions has been used for cell tracking.21

19

F MRI is able to image

implanted cells with high specificity due to the lack of detectable fluorine in biological
tissue.22,23 Quantification of implanted cells is possible since the 19F MRI signal intensity
is linearly related to the number of

19

F-labeled cells. Unlike PET/SPECT probes,

19

F

does not undergo radioactive decay allowing for longitudinal studies without radiationinduced toxicity to the implanted cells or surrounding tissue. Furthermore, the first
clinical application of

19

F-MRI cell tracking for DC immunotherapy was recently

reported, showing the technique is both feasible and safe for human application.24
In this paper, we investigated the feasibility of quantifying MSC fate in two different
immune environments. This was performed by comparing the change in 19F-MRI signal
strength over time using two popular transplantation models. A syngeneic transplant
model, with mouse MSCs (mMSC) implanted in an immune-competent mouse host, was
compared to a xenograft model produced from human MSCs (hMSC) implanted in an
immune-compromised mouse. Our goals were: i) to quantify the apparent cell number
non-invasively for 2.5 weeks and ii) to validate in vivo

19

F-MRI quantification results

with fluorescence microscopy and immunohistochemistry.

3.2 Methods
3.2.1

MSC Culture and Labeling

hMSC came from bone marrow donated by healthy young adult volunteers after written
informed consent according to a protocol approved by University Health Network
Research Ethics Board (Toronto, Canada)25. hMSC were cultured as described by Ribot
et al.19 Briefly, hMSC were grown in low glucose Dulbecco’s Modified Eagle’s Medium
until passage 4. mMSC initially derived from the bone marrow of C57Bl/6 mice and
expressing green fluorescence protein (GFP+) were purchased from Cyagen Bioscience
Inc. (Catalog # MUBMX-01101). The cells were cultured in OriCellTM Mouse MSC
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Growth Medium until 90% confluent. The mMSC were passaged once before labeling
and implantation.
MSC were labeled with the red fluorescent perfluoropolyether agent, Cell Sense (CSATM-DM Red; CelSense Inc. Pittsburg, USA)26. Labeling took place over 24 hours at a
concentration of 2.5mg/mL. After incubation, the cells were washed 3 times with Hank’s
balanced salt solution (HBSS), harvested with Trypsin, spun down and counted. At this
stage the cells were tested for viability using trypan blue exclusion. Intracellular

19

F

content of cells was determined using NMR spectroscopy, as we have described
previously.19

3.2.2

MSC Implantation

1.5x106 Cell Sense-labeled hMSC in 100µL of HBSS were implanted intramuscularly
into the right hindlimb muscle of immune-compromised, nude mice (nu/nu, Charles
River Canada) to produce a xenograft model (n=7). In a similar manner, 2.0x106 labeled
mMSC in 100µL of HBSS were implanted into immune competent, C57Bl/6 mice
(Jackson Laboratories) producing a syngeneic model (n=8). In both cases, the injections
were performed under 2% isoflurane anesthesia. All experiments involving human and
mouse stem cells, as well as animal use, were approved by the Western University
Animal Use Committee (AUP 2009-042).

3.2.3

MRI

All images were collected using a 9.4T Varian small-animal MRI scanner. A 3D
balanced steady state free precession (bSSFP) sequence was used for both proton and
fluorine imaging. Cell pellets containing 2x105, 4x105, 6x105, 8x105, 1x106 and 2x106
19

F-labeled MSC were imaged alongside a CS-1000 reference tube of known fluorine

concentration (7.3x1016

19

F/µL).

MRI was performed using a dual-tuned birdcage

volume coil (diameter 2.2cm, length 5.1cm), tuned to 400.2 MHz and 376.8 MHz for
proton and fluorine imaging respectively. For proton imaging of cell pellets the scan
parameters were: repetition time (TR)=3.8ms, echo time (TE)=1.9ms, receiver bandwidth
(rBW)=125kHz, flip angle (FA)=30°, averages=2, resolution=200x200x200µm3.

For
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fluorine imaging the parameters were: TR=3.5ms, TE=1.8ms, rBW=25kHz, FA=70°,
averages=250, resolution=1x1x2mm3. Total protocol time for both proton and fluorine
imaging was under 90 minutes. The pellets were imaged on three separate occasions to
test quantification variability.
Mice containing 19F-labeled MSC implantations were imaged at four time points, starting
on day 0, after implantation. The scan parameters were the same for the in vivo mouse
MRI as described above. During scanning the mice were anesthetized with 2% isoflurane,
with breathing rate and temperature monitored. Due to the high sensitivity of bSSFP to
off-resonance frequencies27, a narrow 1.5kHz sinc pulse was used to excite only the 19F
agent.

3.2.4

Image Analysis and Quantification

Prior to image analysis, a signal correction was applied to the 19F datasets by subtracting
a constant value (x) from all voxels within the dataset using the image program,
ImageJ.28,29 The value of x was equal to the signal of the single voxel containing the
lowest signal throughout the entire dataset. This linear translation acted to left-shift the
data distribution to begin at zero. Quantification was performed using Voxel TrackerTM
software, as described by Srinivas et al.30 Briefly, in the

19

F MR images, the signal

contained within a hand drawn ROI is summed and compared to the average signal
produced by the reference tube of known concentration (2.6x1016

19

F spins/µL). This

value (X) provides the total number of 19F spins located at the ROI. NMR spectroscopy
was then performed using a known number of the same transplanted cells, along with a
second

19

F source containing a known number of

19

F spins. By comparing the relative

NMR signals, the number of 19F spins per cell (Y) is obtained. Division of X by Y yields
the number of cells located at the ROI. Significance between time-points was assessed
using a repeated measures, one-way ANOVA.

3.2.5

MSC Immunohistochemistry

Mice were sacrificed and perfused with 4% paraformaldehyde following the final
imaging timepoint. In addition, one mouse from each model was sacrificed and perfused
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on Day 0 for comparison. The hindlimb muscle was extracted and cryoprotected with
increasing concentrations of sucrose (10%, 20%, 30%) before freezing in OCT medium.
Tissue was sectioned with a cryostat. Fluorescence microscopy was performed to image
the red fluorescent

19

F-label as well as the GFP+ mMSC with a Zeiss AXIO Imager

microscope (Carl Zeiss Canada Ltd). Immunohistochemistry staining was then performed
on these sections. Macrophage presence was assessed using Biotin anti-mouse
macrophage (F4/80) monoclonal antibody (Cedarlane Laboratories Ltd) with 3,3’Diaminobenzidine (DAB) counterstain.

3.3 Results
In vivo results
Figure 12A shows that labeling with the

19

F agent did not negatively affect the mMSC

cellular viability. The viability of the hMSC was slightly decreased following labeling.
Previous work by our group demonstrated that the perfluorocarbon, Cell Sense, does not
negatively impact differentiation of labeled hMSC into osteogenic or adipogenic
lineages.19 NMR revealed the mean cellular loading of

19

F varied between experiments

and cell types within the range of 8.2x1010 to 2.4x1011 atoms.
Quantification of 19F in cell samples
Quantification of the

19

F signal was tested in vitro using Cell Sense labeled mMSC

pellets. Imaging was performed at 9.4T on six cell pellets ranging from 200k to 2 million
cells. Figure 13 represents the average quantification and standard deviation from
imaging the cell pellets on three different occasions. We observed a strong linear
relationship between the MR quantification and the real cell number, with an R2=0.98.
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Figure 12: (A) Cellular viability was investigated before and after labeling with the
19

F-agent, Cell Sense. Although a statistically significant difference was observed in

hMSC after labeling, the viability remained high (>80%) in all experiments. There
was no significant difference in mMSC viability. (B) Mean cellular loading was
determined by performing NMR spectroscopy on a known number of cells alongside
a reference peak with a known number of 19F atoms. We observed variation in
cellular loading of both hMSC and mMSC between experimental batches.
However, this variation does not affect in vivo 19F quantification since each
transplant was only compared to its specific cellular loading.
In vivo detection of 19F MRI signal
19

F-MRI signal was initially detectable in all mice following intramuscular injection of

2.0x106 mMSC or 1.5x106 hMSC. On day 0 quantification of the in vivo signal agreed
very well with the number of implanted cells (Fig. 14). Over time the signal decreased in
both models. In the immune competent model (Fig. 14A), a significant difference was
observed in the

19

F MRI signal over time [F(1.703,6.812)=39.85, p<0.001]. Post hoc

Tukey tests showed there was a significant difference in 19F signal between day 3 and day
9 (p<0.01), and day 9 and 16 (p<0.05). At 16 days post implantation only two mice had
any detectable signal remaining.

Signal in the immune-compromised mice (Fig. 14B)

decreased more slowly [F(1.378,5.511)=30.97, p<0.01], with significance from day 0
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Figure 13: in vitro validation of 19F-MRI quantification accuracy. Quantification
was validated in a phantom study using cell pellets ranging from 2x105 to 2x106
MSC. Pellets were imaged three times, with the error bars representing the
standard deviation between scans. The 19F-MRI quantification is in very strong
agreement with the true number of cells, and has a Pearson correlation coefficient of
0.99. The red line represents the ideal result of a 1:1 correlation.

Figure 14: Comparison of 19F-labeled cell detection in two transplantation models
over time (A) Following implantation of 2x106 mMSC, 19F-MRI was used to quantify
the number of cells remaining over 16 days. By day 16, only 2/7 mice had any
detectable signal remaining. A significant difference from day 0 is denoted by

,

from day 3 by u, and from day 9 by n. (B) The number of detectable cells over a
similar time period following a transplant of 1.5x106 hMSC. 19F signal was found to
decrease at a slower rate, with observable signal in all mice at the endpoint.
Statistical significance is denoted in the same way as A.
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only detectable on day 17 (p<0.01).

Furthermore, at this endpoint all immune-

compromised mice still had detectable signal.
Representative MR image data, fluorescence microscopy, and H&E obtained on day 0 is
shown in Figure 15. Overlays of the 19F MRI onto the proton image at day 0 are shown in
15A and E for the immune competent and immune compromised mice, respectively.
Figures 15B and F show that the red fluorescence signal from the 19F labeling agent can
be detected on day 0 in both models. The green fluorescence associated with the GFP+
mMSC was also visible at the site of their implantation on day 0 (Fig. 15C). Overlaying
the two fluorescent images revealed co-localization, with a Pearson’s correlation
coefficient of 0.80, between the red fluorescent 19F agent and the GFP+ mMSC in Figure
15D. The corresponding H&E stained tissue sections agree with the location of the
implant within the muscle (Fig. 15G,H).
Figure 16 shows representative MR image data, H&E, F4/80 immunohistochemistry and
fluorescence microscopy obtained at the experimental endpoint. By day 16 post
implantation no

19

F-MRI signal from the mMSC was detectable in 5/7 of the immune

competent mice. One of these mice is shown in Figure 16A where the only
comes from the reference tube. In contrast,

19

19

F signal

F signal was still detectable in all of the

immune compromised mice at day 17, with an example shown in Figure 16E.
Fluorescence microscopy revealed only a small area of red fluorescence from the

19

F

agent in the immune competent model (Fig. 16B) compared to the immune compromised
(Fig. 16F). In addition, no GFP+ mMSC were detectable in ex vivo samples at endpoint.
H&E staining of the same tissue sections showed cells at the site of the implant, which
corresponded with the

19

F agent’s red fluorescence (Fig. 16C,G). Neighboring tissue

sections corresponding to high red fluorescence were stained for the presence of
macrophages using F4/80. Figure 16D suggests that relatively few macrophages were
detected in the immune competent model at endpoint. In contrast, the F4/80 stain
revealed macrophages (Fig. 16H) in the same region as the red fluorescence from the

Figure 15: (A, E) Representative MRI from mice receiving either 2x106 mMSC or 1.5x106 hMSC respectively. The day 0 in
vivo 19F-MRI quantification correlates very well with the number of implanted cells. The reference tube is marked by “R”. (B)
The red fluorescent fluorine agent is clearly visible in the tissue of the immune competent model, (F) as well as in the immunecompromised model. (C) Furthermore, the GFP+ mMSC are observable within the tissue section. (D) Overlaying the two
fluorescent images, reveals the 19F agent colocalized with the GFP+ mMSC, as expected. (G, H) H&E stained tissue sections
corresponding to the fluorescence microscopy clearly show the implant site of the mMSC and hMSC respectively. Scale bars
in all images represent 250µm

Figure 16: By day 16, 5/7 immune competent mice had no 19F-MRI signal remaining (A). The reference tube is marked by
“R”. (B) Fluorescence microscopy of the muscle agreed with little red fluorescence. No GFP+ mMSC were detectable by
fluorescence microscopy, suggesting the original mMSC are no longer present. (C) H&E staining reveals cells at the implant
site which correlates with the remaining 19F red fluorescence. (D) Immunohistochemistry staining of adjacent tissue sections
with the anti-F4/80 antibody reveals a few macrophages at this location in the immune competent model. (E) At endpoint, all
immune compromised mice had detectable 19F-MRI signal remaining. (F) More red fluorescence is visible, and (G)H&E
staining again correlates well with the regions of red fluorescence. (H) Macrophage staining reveals many more F4/80 positive
cells at the site of implantation corresponding to the regions of red fluorescence. Scale bars represent 250µm.
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19

F agent in the immune compromised model. The number of macrophages visually

corresponded with the amount of remaining red fluorescence in both cases.

3.4 Discussion
In vivo quantification of MSC
This study demonstrates the ability to use

19

F-MRI cell tracking to detect and, most

importantly, to measure the signal from transplanted stem cells in vivo. It is difficult to
quantify cell number using other MRI cell tracking techniques. Numerous studies have
previously reported on the challenges associated with quantification of signal loss due to
iron-labeled cells.19,20,31 This has, so far, narrowed the implementation of cell tracking for
monitoring the fate of transplanted cells. In this study, we show excellent correlation
between the number of labeled cells implanted and the number of cells counted on day 0
by

19

F-MRI. This capability will pave the way for MRI to be used in confirming the

delivery of therapeutic cell transplants.
The importance of accurate delivery of cells to a target tissue cannot be overstated. In
preclinical investigations often stem cells will be transplanted then a set time allowed to
lapse before the transplanted tissue is removed and processed for microscopy, to
determine whether stem cells remain in the tissue. In many cases, only a very small
sample of the transplanted tissue is evaluated. In a previous study we used MRI to track
iron-labeled MSC in a mouse model of spinal cord injury32. Our in vivo imaging revealed
that the challenging intrathecal injections of MSC were imprecise approximately 25% of
the time; injected cells were often being deposited in tissue above the cord or leaking out
of the cord. The histological assessment in this study involved the analysis of 1cm of cord
tissue on either side of the transplant site, six weeks after transplantation. Without MRI, a
negative observation of MSC by microscopy would have been taken as failure to engraft
rather than due to a missed injection. Injection confirmation with

19

F MRI would have

the additional advantage of determining how many cells were properly injected and
remain at the site.
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In a first-in-man study, MRI and scintigraphy were used to assess the success of
intranodal injections consisting of a 1:1 mixture of iron- or indium-labeled dendritic cell
(DC) for cancer therapy in melanoma patients.33 Despite these cell injections being
performed under ultrasound guidance the MRI of iron-labeled DC revealed that in 3/8
cases DC were injected near, but not in, the target lymph nodes.33 These findings make it
clear that the outcome of this cell therapy on these patients would not be properly
evaluated without knowledge of proper delivery of DC to the nodes. For DC therapy
knowledge of the number of cells delivered to a lymph node is especially critical since
DC migration to nodes correlates with effective stimulation of T cells.

19

F-MRI therefore

presents a promising solution to the clinical problem of verifying both the location and
number of cells within the region of interest immediately following administration of
treatment.
In these experiments the hMSC and the mMSC were both capable of taking up sufficient
19

F label for in vivo detection, without decreasing viability below 80%. We observed

some variation in the number of 19F atoms loaded per cell between experiments, although
the average loading was not significantly different for mouse versus human MSC. The
cell size is one of the more important factors influencing the labeling with Cell Sense and
mouse and human MSC are approximately 30 microns in diameter. The fact that it is
possible to obtain robust measurements of the number of cells detected by MRI, despite
inter-experiment variation in the number of 19F atoms per cell, is another positive feature
of this type of cell tracking. The variation in
confounding factor in the

19

19

F/cell between batches is not a

F-MRI quantification since the mean cellular loading is

determined for each transplantation. This is particularly important when considering
clinical translation, since 19F uptake is expected to vary between cell donors.
Monitoring the fate of MSC over time
This study also revealed some interesting information about tracking cell fate over time
with

19

F MRI. We studied the fate of MSC in two different models: mMSC implanted

into healthy wild type C57Bl/6 mice (immune competent model) and hMSC implanted
into healthy nude mice (immune compromised model). We believe the MSC and

19

F-
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label, underwent clearance from the sites of implantation in muscle at different rates,
which is not unexpected since the two different mouse strains have very different
immune systems.
In the immune competent model, 5/7 mice had no MRI detectable 19F signal remaining at
the site of injection by the endpoint. The other 2 mice had just 4% and 10% of the
original signal remaining. There were no GFP+ cells detected by fluorescence
microscopy but there was some red fluorescence, indicating that some of the

19

F label

persisted at the site but that it was not within GFP+ mMSC. The small amount of residual
red fluorescent signal corresponded with F4/80 staining suggesting that some transfer of
19

F label from mMSC to macrophages has occurred. The decline in the signal is likely the

result of several different things happening at the transplant site. First, many MSC will
die early after their direct transplantation into a tissue. Second, the label may be diluted
by MSC proliferation, or degradation of the label within MSC. Third, MSC may have
migrated away from the implant site; although we did not detect

19

F signal in other

nearby locations.
The fact that for 5/7 mice no endpoint MRI signal was detected, even though red
fluorescence was still observed in the tissues (as for the example shown in Fig 16A-D) is
most likely because the number of cells containing the red fluorescent
small. This small amount of

19

19

F label is very

F signal is below the in vivo detection limits of the MRI

protocols used in this study.
In the immune compromised model the

19

F signal persisted in all mice until the

experimental endpoint. Much more red fluorescence was observed in these tissues at the
implant site and this corresponded well with F4/80 staining, again suggesting that the
persistent

19

F signal was related to transfer of label from hMSC to macrophages. A

limitation of this study was that our hMSC were not also GFP+. This would have allowed
us to say with more confidence that the

19

F label was associated with macrophages and

not the implanted hMSC. Clearance of label and macrophages may have been slower in
these mice because of the inhibited immune system and lack of rejection response.
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Our observation of bystander cell uptake of

19

F cell label is supported by a study by

Boehm-Sturm et al.34 In their study in vivo imaging of the location, density, and survival
of neural stem cells implanted in the brain in a stroke model was performed using
MRI in combination with bioluminescence imaging. The signal from

19

19

F

F labeled stem

cells persisted for more than 4 weeks after implantation while, over the same time period,
the bioluminescence declined, indicating stem cell death.

Immunohistochemistry

staining also revealed the presence of microglia/macrophages at the site of implantation.
Terrovitis et al. looked at the retention of iron labeled stem cells implanted into immune
competent rats.20 Either rat or human cardiac-derived stem cells were injected
intramyocardially. In both cases MRI signal loss due to iron was detected for 3 weeks
post cell injection and correlated with the presence of iron containing macrophages in
histology. Although the area of signal void decreased over time, substantial signal void
persisted at the injection site in all mice. Since proton MRI is sensitive to even small
numbers of iron-labeled cells this form of cell tracking is most susceptible to the
misinterpretation of cell fate. Previous studies performed in our lab using iron labeled
syngeneic MSC also revealed the persistence of an iron signal void past 21 days in
immune competent mice.14

3.5 Conclusions
In summary, 19F MRI can be used to provide immediate assessment of implanted cells
with excellent correlation between implanted cell number and in vivo quantification.
Over time, as the cells are cleared from the transplantation site, transfer of the 19F label to
bystander cells may confuse interpretation of the change in 19F signal. With the first-inman studies of 19F MRI recently completed, this result will be particularly relevant when
translating this technique into the clinic.24
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Chapter 4

4

Application of Dual 19F- and Iron-Cellular MRI Agents to
Track the Infiltration of Immune Cells to the Site of a
Rejected Stem Cell Transplant‡

4.1 Introduction
Cellular magnetic resonance imaging (MRI) has proven to be an effective technique for
non-invasive tracking of cellular therapeutics. The absence of signal attenuation with
tissue depth and the lack of ionizing radiation allows for long-term monitoring without
risk to the patient or therapeutic cells. MRI cell tracking relies on pre-labeling cells with a
non-invasive imaging agent to render them MRI detectable. To date, most cellular MRI
has been performed with one of two labeling agents. The first, and most common, is
superparamagnetic iron oxide (SPIO) nanoparticles. Iron-labeled cells are indirectly
detected as a region of signal void. When subjected to an external magnetic field, SPIOs
change the net local magnetization. This acts to increase the R2* relaxation rates of the
surrounding nuclear spins. In the MR image, this results in signal loss or regions of
hypointensity. Iron-based cell tracking has the advantage of being highly sensitive, due to
the large magnetic field inhomogeneity effect produced by SPIO which is indirectly
detected through the abundant water proton signal; a so-called blooming artifact. Single
cell imaging has previously been demonstrated with iron agents1,2. The technique is
limited by the challenges associated with quantifying signal loss, due to the non-linear
relationship with iron concentration3. This makes it difficult to quantify cell number and
track changes in cell number over time.
___________________
‡

This chapter was previously published and is included here with permission: Gaudet JM,
Hamilton AM, Chen Y, Fox MS, and PJ Foster (2016) “Application of dual 19F and iron
cellular MRI agents to track the infiltration of immune cells to a site of a rejected stem
cell transplant” Journal of Magnetic Resonance in Medicine. Early view online

68

Over the past decade, fluorine-19 (19F) based cell tracking techniques have become of
increased interest4. Utilizing the MRI sensitive 19F nuclei, this method involves the direct
measurement of signal from

19

F spins and has no effect on proton contrast. Since

biological tissue has negligible levels of 19F, no background signal is present and the 19F
signal is inherently quantitative.

However, the relative insensitivity of the nuclear

magnetic resonance signal means that thousands of cells per voxel are required for
detection. The minimum number of cells required for detection varies between cell types
depending on intracellular 19F uptake; which ranges between 1010-13 19F/cell.
A major focus of MRI cell tracking has been on understanding the in vivo behaviour of
transplanted stem cells5,6. Prior to implantation, stem cells are labeled with an MR
imaging agent in culture. Iron and 19F-based agents have both been utilized to investigate
the location, migration and survival of stem cells 7–10. With applications in neural, bone,
cardiac, and cartilage reconstruction, stem cells have a high potential for therapeutic
application. In addition to cell restoration, recent studies have highlighted the important
role stem cells play in promoting growth within the local microenvironment through the
secretion of trophic factors11–13. Unfortunately, this therapeutic potential is often limited
due to stem cell death. In the days following administration, many stem cells undergo
apoptosis due to the stresses of administration and inadequate access to nutrients12,14–17.
Cytokines released by the apoptotic stem cells attract macrophages to the implant site,
triggering an immune response by the host18–20. The immune cell infiltration occurs
rapidly, often within the first week after transplant21.
A number of studies have now demonstrated that tracking iron-labeled stem cells with
MRI cannot be used to reveal graft rejection in vivo8,22–28. This is because it is not
possible to reliably distinguish between live and dead iron-labeled cells in MRI. Bernau
et al. shows that the death of iron-labeled human neural progenitor cells transplanted into
the rat brain could be identified in vivo by bioluminescence imaging (BLI) but not by
MRI; the BLI signal decreased below a detectable level with cell death while the MRI
signal remained the same due to transfer of the iron label to bystander macrophages26.
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Another cellular MRI strategy for detecting rejection has been to image the immune cells
that infiltrate a failed graft. Here, iron particles are administered i.v. and engulfed by cells
of the reticuloendothelial system. MRI is typically performed one day later to visualize
the accumulation of iron-labeled cells, mainly macrophages and monocytes, at the site of
the transplantation. A significant decrease in the MR signal intensity indicates rejection
has occurred. This approach was first used to detect acute rejection in a model of rat renal
transplantation in 200029. Since then, numerous studies have investigated the application
of i.v. iron for detecting organ and stem cell rejection29–32. The potential for clinical
translation of this technique has been recently demonstrated with the clinical i.v.
administration of an ultra-small SPIO (USPIO), ferumoxytol33,34.

19

F agents have been

used in a similar manner within pre-clinical models for imaging inflammation35–38.
The purpose of this study was to investigate the use of 19F- and iron-based cellular MRI
techniques in concert to simultaneously monitor transplanted stem cells and infiltrating
macrophages. Human mesenchymal stem cells (hMSC) were labeled with a

19

F agent

prior to intramuscular implantation into the mouse hind-limb and macrophage infiltration
resulting from rejection of the transplant was visualized by in situ labeling with i.v.
administered USPIO nanoparticles.

4.2 Methods
4.2.1

hMSC Culture and Labeling

hMSC were collected from the bone marrow of healthy, young adult volunteers donated
with written informed consent according to a protocol approved by University Health
Network Research Ethics Board (Toronto, Canada)39. The cells were cultured in lowglucose DMEM with 10% (Thermo Fisher Scientific Corp, Waltham, MA, USA) until
90% confluent.
hMSC were labeled with the red fluorescent perfluoropolyether agent, Cell Sense (CS1000-ATM:DM Red, CelSense Inc., Pittsburgh, USA)40. Labeling took place over 24
hours at a concentration of 2.5mg/mL. After incubation, the cells were repeatedly washed
with Hank’s balanced salt solution (HBSS) before and after TrypLETM dissociation. The
viability of the isolated cells was tested by trypan blue exclusion. Intracellular 19F content
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of cells (Fc) was determined using NMR spectroscopy, as we have described
previously28.

4.2.2

hMSC Implantation

1x106 Cell Sense labeled hMSC in 50µL of HBSS were implanted intramuscularly into
the right hindlimb muscle of 14 immune competent, C57Bl/6 mice (Jackson Laboratories,
USA), as shown in figure 17. This model was utilized to promote a strong immune
response against the human cells by the host. The injections were performed under 2%
isoflurane in 100% oxygen anesthesia. 24 hours after hMSC implantation, the mice were
randomly assigned to one of two groups. Group A (n=7) received no further treatment.
Group B (n=7) received 0.5mmol/kg of the ferumoxytol Feraheme (AMAG
Pharmaceuticals, Waltham, USA) i.v. via tail vein 24 hours after the hMSC implantation.
Two additional groups of 3 mice were used for controls. Group C (n=3), received 50µL
HBSS on Day 0 instead of hMSC, followed by 0.5mmol/kg of Feraheme i.v. 24 hours
later. Group D (n=3) received 1x106 unlabeled hMSC, followed 24 hours later by 200uL
of i.v.

19

F agent (VS-1000, CelSense Inc., Pittsburgh, USA). All experiments involving

human stem cells, as well as animal use, were approved by the Western University
Animal Use Committee.

4.2.3

MRI

All images were collected using a 9.4T Varian small-animal MRI scanner. A 3Dbalanced steady state free precession (bSSFP) sequence was used for both 1H and

19

F

imaging. Animals were imaged alongside an agarose diluted Cell Sense reference tube of
known

19

F concentration (3.33x1016

19

F/µL). MRI was performed using a dual-tuned

birdcage volume coil (diameter 2.2cm, length 5.1cm), tuned to 400.2 MHz and 376.8
MHz for 1H and 19F imaging, respectively. For 1H imaging the scan parameters
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Figure 17: Human MSC were labeled with a 19F agent prior to being implanted into
the mouse hindlimb muscle. Quantification of the 19F signal performed at this
timepoint shows a strong correspondence with the expected number of cells. 2) One
day after implantation, iron nanoparticles were administered i.v. These
nanoparticles are scavenged from the bloodstream by macrophages and monocytes,
rendering them MRI detectable. 3) Two days after implantation, iron labeled
macrophages have migrated to the site of implant. The labeled macrophages are
visible in MR images as signal voids at the site. 19F-MRI signal is also significantly
decreased as the iron quenches the signal.
were: repetition time (TR)=5.0ms, echo time (TE)=2.5ms, receiver bandwidth
(rBW)=78kHz,

flip

angle

resolution=200x200x200µm3.

(FA)=30°,
For

19

phase

cycles

(PC)=4,

averages=3,

F imaging the parameters were: TR=5.5ms,

TE=2.8ms, rBW=25kHz, FA=70°, PC=4 averages=30, resolution=0.5x0.5x1mm3.
Imaging parameters were chosen based upon optimization work performed in previous
studies27,28. Total protocol time for both 1H and 19F imaging was under 60 minutes.
Mice were imaged immediately following hMSC implantation (day 0) and on days 2, 6,
10, and 14. During scanning the mice were anesthetized with 2% isoflurane in 100%
oxygen, with breathing rate and temperature monitored. A 1ms Gaussian shaped
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excitation pulse was used to prevent detection of 19F signal from the isoflurane anesthetic,
as described in more detail previously27.

4.2.4

Image Analysis and Quantification

Prior to image analysis a signal correction was applied to the 19F datasets by subtracting
the value of the voxel containing the lowest signal in the dataset using ImageJ
software41,42.

19

F signal quantification was performed using Voxel TrackerTM software.

The total signal contained within a hand drawn ROI produced by the 19F labeled cells was
compared to the average signal produced by the reference tube of known concentration
(3.33x1016

19

F spins/µL). This information was used alongside Fc measured with NMR,

to quantify the apparent number of cells located at the ROI, as described by Srinivas et
al43. Significance between time-points was assessed using a repeated measures, one-way
ANOVA using GraphPad Prism 6 software (GraphPad, San Diego, CA, USA).

4.2.5

Immunohistochemistry

Mice were sacrificed and perfusion fixed with 4% paraformaldehyde (PFA) following the
final imaging timepoint on day 14. In addition, two mice from group A and B were
sacrificed and perfused; 24 hours following i.v. iron injection (day 2) for comparison.
Tissue was cryoprotected with increasing concentrations of sucrose (10%, 20%, 30%)
before freezing in OCT medium, and sectioned at 12µm thickness. A DAB-enhanced
Prussian Blue stain was used to detect iron. Prussian Blue staining was performed with
the slides were placed in 4% potassium ferrocyanide (Fisher Scientific, Waltham, MA)
and 4% hydrochloric acid. After washing, DAB- intensification was performed 3,3’diaminobenzidine tetrahydrochloride (DAB; Sigma Aldrich, St Louis, MO) staining.
Lectin immunofluorescence was then performed on the iron-stained sections to identify
macrophages. First, sections were incubated with biotinylated isolectin B4 (Sigma
Aldrich) and Triton X-100 overnight. Sections were then incubated in the dark with
streptavidin conjugated with fluor 488 (1:500; ThermoFisher Scientific). Finally, tissue
was counterstained with Hoechst stain for detection of cell nuclei. Fluorescence
microscopy was performed to image the red fluorescent

19

F-label as well as the green
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fluorescent lectin label with a Zeiss AXIO Imager microscope (Carl Zeiss Canada Ltd).
Slides were assessed through visual inspection.

4.3 Results
hMSC labeling with 19F
NMR revealed the cellular loading, Fc, varied between study replications within the range
of 8.2x1010 to 2.4x1011

19

F atoms/cell. This large variability in labeling efficiency

between replications has been previously observed in numerous studies with human
cells28,44. Previous work by our group demonstrated that labeling hMSC with Cell Sense,
does not negatively impact viability or differentiation into osteogenic or adipogenic
lineages27,28.
In vivo detection of 19F-labeled hMSC
On the day of implantation (day 0) the

19

F-labeled hMSC were visible in all mice in

Groups A and B (Figure 18). In Group A, the mice that received only 19F labeled hMSC,
the 19F signal gradually decreased between days 0 and 14 post implantation (Figure 18AE). This result is expected as the implanted hMSC die, and the 19F label is dispersed. At
the endpoint, the average 19F signal was 22±11% of the initial value. One mouse within
this group had no detectable signal in the final imaging session.
In Group B, the mice that received i.v. Feraheme 24 hours after the hMSC implantation, a
large region of signal void was visible at the implant site in day 2 proton images (Figure
18G, day 2). Coincident with this was a significant decrease in the detected

19

F signal

compared to the day 0 signal from the same group. This is due to quenching of the

19

F

signal by the spin dephasing produced by nearby iron nanoparticles. Between days 2 and
14 the

19

F signal remained lower in Group B for each time point compared to Group A

and the region of signal void persisted in the proton images. Signal loss was also
observed in the lymph nodes, spleen and liver following i.v. Feraheme administration,
resulting from the uptake of iron nanoparticles by macrophages of the reticuloendothelial
system.
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Figure 18:
Representative images
at each time point
from Group A and B.
Images were produced
by overlaying 19F
signal onto proton
images for anatomical
context. Mice were
imaged over 14 days
following
intramuscular
injection of 19F agent
labeled hMSC on Day
0 (A,F). Detected 19F
signal from the hMSC
implant is denoted by
a yellow arrow in each
image. Quantification
of the apparent
19

number of hMSC from F signal was calculated using reference tubes of known 19F
concentration. The reference tube is visible in panels I & J, and partially visible in
panel F. Mice in group A (A-E), received no further treatment besides imaging.
Group B mice (F-J) received i.v. iron on Day 1 following fluorine-labelled stem cell
transplant. The i.v. iron is taken up by macrophages and monocytes in the
bloodstream. On Day 2 (G), a large region of signal void is visible at the implant
site. The presence of signal void indicates iron labeled immune cells have migrated
to the implant site. This signal void region persists at each time point until endpoint
on day 14 (G-J). No signal loss was observed in the muscle of the untreated leg. In
addition to the implant site; voids were also visible in the lymph nodes, lymphatics,
liver, and spleen.
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Quantification of the

19

F signal for Groups A and B is shown in Figure 19. For both

Groups A and B we present the apparent number of hMSC, determined as described in
the methodology. On day 0 the mean values for cell number were 0.99±0.08 x106 and
1.08±0.08 x106 for Groups A and B, which agree strongly with the number of cells
implanted (i.e., 1x106 cells). In Group A, the apparent cell number decreased between
days 0 and 14 post implantation. Significant differences in the mean apparent cell number
were observed between days 0 and 6, days 2 and 10, and days 6 and 14.
quantification indicates that over time the

19

This

F labeled hMSC diminish in number, most

likely due to cell death and clearance.

Figure 19: Quantification of 19F signal at each time point. Significance between
groups A&B at the same time point is donated with (#). Within the same group,
over time is donated (†) between the previous time point and (‡) for between two
time points. On day 0, both group A and B signal is in strong agreement with each
other and with the expected number of implanted hMSC (1x106). Overtime, in
group A 19F signal decreased at each subsequent time point. This is likely due to cell
death and 19F agent clearance by the immune system. In group B, following i.v. iron
administration there is a significant decrease in 19F signal (day 2) compared to the
previous time point and the Group A mice at the same time point. After this there is
no significant change in 19F signal in group B at any other time point.
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For Group B, the mean apparent cell number sharply declined between days 0 and 2. This
significant decrease reflects the presence of iron-positive macrophages, which has
quenched the 19F signal from the labeled hMSC45. Between days 2 and 14 there was no
significant change in apparent cell number, suggesting that the iron-labeled macrophages
persist at the implant site. When comparing between Groups A and B a significant signal
difference was observed on days 2 and 6. Control mice, which received HBSS instead of
hMSC, followed by i.v. Feraheme (Group C), did not have any signal voids within the
muscle at any time point (Figure 20). For Group D mice, which received unlabeled
hMSC on day 0 and i.v. 19F agent on day 1, the 19F signal was detected at the site of the
cell implant in images acquired on day 2 and did not change significantly for the duration
of the experiment (Figure 21).

Figure 20: A sham model of Group B was produced by performing an
intramuscular injection containing only saline on day 0, followed by intravenous
iron on day 1. On day 2, no proton signal voids were detectable within the muscle.
Signal voids were detectable within the bone marrow, lymph nodes, and liver,
indicating the iron injection was successful. These regions are marked by white
arrows.
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Figure 21: Inflammation was assessed by performing an intramuscular injection
containing unlabeled hMSC on day 0, followed by i.v. 19F agent on day 1 [Group D].
A representative 19F/1H overlaid image from day 2 shows a similar inflammation
pattern within the muscle [white arrow] as observed with iron oxide (A). On day 2 a
mean of 2.5±1.3x1018 19F spins was detected at the transplant site. 19F signal was also
detected at the lymph node [yellow arrow]. Unlike Group B, the 19F-labeled
macrophages can be quantified over time (B). The relative signal normalized to day
2 within each mouse provides a measure of change in inflammation over time. No
significant differences were observed at any time point.
Microscopy and Immunohistochemistry
Macrophages in the muscle tissue were identified through low magnification (10x)
fluorescence microscopy of lectin immunohistochemistry-stained sections (Fig 22A&E).
In mice euthanized on day 2, macrophages were localized within and surrounding the site
of hMSC implantation, which was visible by the red fluorescence associated with the 19F
agent (Fig 22B). An overlay of the green, red, and blue (Hoescht) images revealed that
there were macrophages within the hMSC tract that appear to be associated with the 19F
agent and other macrophages which were not. This is evident in the inset of Figure 22D
where yellow suggests the co-localization of the fluorescence from the green
macrophages and red 19F agent. In mice euthanized on day 14, macrophages distribution
appeared different compared to day 2 with green fluorescent signal predominately visible
within the stem cell tract (Fig 22E). This was coincident with a visible decrease in the
area of red fluorescence (Fig 22B), which agreed with the finding of decreased

Figure 22: Fluorescence microscopy showing the intramuscular injection track on day 2 (A-D) and day 14 (E-H).
Macrophages were stained with a green fluorescent lectin+ marker. At the early time point on day 2, macrophages are visible
both within and surrounding the stem cell track (A). By endpoint on day 14, macrophages are only found within the
transplant track (E). Scale bars denote 300 µm. The red fluorescent 19F agent is visible within the stem cell track from the
same tissue sections. More red fluorescence is visible on day 2 (B) then on day 14 (F), in agreement with MRI signal. Cell
nuclei were detected with blue Hoeschst staining (C,G). Merged fluorescent images show some bystander labeling of
macrophages, appearing as yellow. On day 2, there are few bystander labeled macrophages, as indicated by the separation
between red and green fluorescent markers (H). However, by day 14 the majority of 19F agent is contained within
macrophages (H). This is highlighted within the magnified inset in the lower left corner (width 150µm).
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F signal by MRI. The overlay (Fig 22H) suggests that 14 days after hMSC implantation

the majority of the macrophages are restricted to the implant site, and are co-localized
with the 19F-labeled hMSC.
Tissue sections for mice in Group B are shown in Figure 23, alongside a representative
proton image obtained on day 2. A large region of signal loss is visible in the muscle
tissue (arrow). Iron stained cells appear dark brown within the muscle tissue sections on
both day 2 (Fig 23B) and day 14 (Fig 23D). More iron-labeled cells were detected at day
14 compared to day 2. The corresponding red fluorescence images of these sections (Fig
23C&E) show the 19F agent and the stem cell tract. The iron was often colocalized with
the 19F signal, especially at day 14, suggesting that macrophages have taken up dead 19F
labeled hMSC and have become co-labeled with iron and 19F.

Figure 23: Signal void is visible in the axial proton images of the muscle after stem
cell transplant on day 2 (A). The transplant site is denoted by the white arrow. No
signal void is visible in the opposite, untreated, hindlimb muscle. Histology reveals
the presence of iron within the muscle tissue on both day 2 (B) and day 14 (D). Scale
bars denote 300µm. The accompanying stem cell track is outlined by the red
fluorescent 19F agent (C,E). More iron is found within the stem cell track at
endpoint compared to day 2; often colocalized with the 19F agent. suggesting it is
contained within bystander labeled immune cells.
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4.4 Discussion
In this study, the use of two different cellular MRI agents for tracking distinct cell
populations was investigated. Pre-labeling of hMSC with a

19

F-agent provided specific

and quantifiable information through the direct detection of the

19

F spins. Intravenous

administration of USPIO allowed for the in vivo detection of hMSC rejection through the
tracking of infiltrating of iron-labeled macrophages which were visualized in proton
images as signal loss, and which impacted the 19F signal from hMSC through 19F signal
quenching.
In agreement with previous studies27, we have shown an excellent correlation between
the number of transplanted cells and the 19F-MRI quantification on day 0 following pre19

labeling of stem cells with

F. This highlights an advantage of

19

F-MRI, that cellular

delivery to the target can be confirmed through localization and quantification of

19

F-

labeled stem cells soon after transplant. In a previous study, stem cell survival and label
retention was demonstrated immediately following transplantation into a murine host27.
The change in 19F-signal over time also provides longitudinal information on the status of
therapy. A reduction in

19

F-signal at the injection site suggests stem cells are either

migrating away from, or dying, at the therapeutic site. Due to the immune competent
xenograft model investigated, this decrease is likely predominately due to stem cell death
and label clearance, as opposed to stem cell migration away from the injection tract46. As
transplanted cells die the 19F signal will be reduced as the label is cleared from the local
tissue. In this study, a decrease in 19F signal was observed for all Group A mice by MRI
and fluorescence microscopy over the 14 days. Microscopy and immunohistochemistry
indicated that macrophages are present at the transplant site in Group A mice as early as
day 2 and that the majority are 19F positive at the endpoint on day 14, in a process known
as bystander labeling. The steady decrease in

19

F signal over time measured by MRI in

Group A suggests that 19F labeled macrophages must be leaving the site. By day 14 since
most macrophages are

19

F positive, stem cell survival at our endpoint is being

19

overestimated by F MRI.
In Group B, the observation of signal voids in proton images in the muscle after i.v.
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USPIO is consistent with the infiltration and accumulation of iron-labeled macrophages.
Previous studies which used i.v. USPIO have shown similar results, and have suggested
that imaging macrophages this way could be used as an early indication of transplant
rejection30. In our study, coincident with the detection of signal loss in proton images was
a significant decrease in

19

F-MRI signal from the stem cells. This is the result of

quenching of the 19F signal by USPIO-labeled cells. After the large reduction in the 19F
signal on day 2, post i.v. USPIO, the 19F signal did not change any further (day 2 to day
14). This observation differed from the steady signal decline observed within Group A,
and is likely due to the inability to accurately quantify 19F signal following the influx of
iron oxide to the site of transplant. In the presence of iron oxide, the

19

F signal is not

linearly related to the concentration of 19F spins and localized changes in relaxation rates
render signal comparison to the external 19F reference tube invalid. Longitudinal changes
in

19

F signal are further complicated due to the saturation of signal quenching in the

presence of large quantities of iron oxide, which may mask changes in iron-labeled cells
over time3. Nevertheless, the significant effect on

19

F signal is advantageous in rapidly

detecting the onset of acute inflammation.
Quenching of 19F signal was first reported in a study by Hitchens et al. that explored the
quenching of signal when 19F-labeled cells are co-labeled with iron nanoparticles45. They
showed that the 19F T2 was significantly reduced in cells that were labeled with both iron
and 19F, but that iron-labeled cells mixed equally with 19F-labeled cells did not impact the
19

F T2. To test the feasibility of detecting different 19F labeled cells in vivo they used a

mouse inflammation model where

19

F and/or USPIO was injected i.v. to label

macrophages. Mice were either administered both the

19

F agent and USPIO i.v. at the

same time or the 19F agent one day and USPIO the next day to try to generate co-labeled
or co-localized cell populations. More

19

F signal quenching was observed when both

agents were administered simultaneously (co-labeled). Quenching was also observed for
co-localized cells in gradient echo Fast Low Angle SHot (FLASH) images, but not in
spin echo Rapid Acquisition with Relaxation Enhancement (RARE) images45. These
important observations set the stage for the work we present here in a mouse model of
stem cell transplantation and rejection.
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Our in vivo results and supportive microscopy suggests that iron-labeled cells nearby 19Flabeled cells (co-localized), and cells which are co-labeled with iron and 19F, both cause
quenching of the 19F signal with our bSSFP imaging protocol. The bSSFP sequence is a
rapid gradient echo imaging method with balanced gradient waveforms, which
establishes a unique steady state47. bSSFP has features of both gradient and spin echo
sequences and image contrast that is predominately related to T2/T1, but can be a
combination with spin-density under some imaging conditions48. Our observation of
signal quenching may also be due to the differences in spatial proximity and iron
concentration present in vivo due to the infiltration of immune cells. Since MRI signal
loss is only linearly related to iron oxide concentration at very low concentrations, the
influx of additional iron oxide over time may not lead to a further decrease in signal3.
Future work is required to better understand signal quenching with bSSFP and to
determine if there is a minimum distance required to distinguish co-localized from colabeled cells.

4.5 Conclusions
In summary, this study investigated the use of two cellular MRI approaches to track
distinct cell types. Stem cells were pre-labeled and directly detected and quantified with
19

F-MRI over time and macrophages were labeled in situ using iron oxide nanoparticles

and imaged with proton MRI to detect the infiltration of immune cells at the transplant
site. To the best of our knowledge this is the first study that has used both proton and 19F
MRI to track two different cell types in vivo with multiple cellular MRI mechanisms.
By combining these well studied MRI cell tracking methodologies, it is possible to noninvasively verify both treatment delivery with

19

F-MRI and to monitor transplant

rejection status with iron nanoparticles. Ultimately, through this technique it may be
possible to obtain additional information on the rejection process and on the ultimate fate
of transplanted stem cells.
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Chapter 5

5

Translation of High-field Fluorine-19 Cell Tracking into
the Clinical Realm

5.1 Introduction
Application of non-invasive, non-toxic, in vivo imaging is essential to the future of
improving cellular therapy. By developing cellular MRI, it might one day be possible to
rapidly determine if a patient will respond to treatment through diagnostic imaging,
without waiting for symptomatic signs. Clinical trial outcomes could be improved by
separating non-responders from those with an unsuccessful cell injection.
The first clinical application of MRI cell tracking was in verifying DC administration for
melanoma immunotherapy1. Dendritic cells are ideally suited for cell tracking translation
due to their clinical relevance and reliance on migration to the lymph node. In 2005, de
Vries et al. tracked mixed SPIO- and

111

In-labeled DC injected intranodally under

1

ultrasound guidance. In this study, MRI was found to be at least as sensitive as
scintigraphic images, with significant improvements in spatial localization. MRI also
showed that a large percentage of guided injections had missed their target injection site,
highlighting the application of cellular MRI in verifying treatment delivery. Since 2005,
iron-based cellular MRI has been used clinically to track a variety of cell types, in
addition to dendritic cells,2 such as: neural stem cells,3,4 hematopoietic stem cells,5 and
pancreatic islet grafts.6 Yet despite the large potential, wide-spread clinical use of iron
oxide based cellular MRI has not been achieved. This is largely due to the unavailability
of a commercial, FDA approved imaging agent. In 2008, Feridex™ an iron-based MRI
reticuloendothelial system contrast agent, was taken off market. Up until this point
Feridex had been used off-label in the majority of cell tracking trials.
In 2014, the first 19F-MRI clinical cell tracking trial was performed using a commercial
perfluorocarbon imaging agent, Cell Sense, to track the administration of DC in patients
with colorectal cancer.7 Dr. Ahrens’ group observed an average of 3.9x1012 19F/cell, with
no decrease in cell viability or changes to phenotype. A Fast Low Angle SHot (FLASH)
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imaging sequence was used on a Siemens 3T clinical MRI system with a 19F-scan time of
9.5 minutes. Patients received either a low dose (1x106 DC, N=2) or a high dose (1x107
DC, N=3) and imaging was performed twice, 4 and 24 hours after administration.

19

F

signal was only detected at the injection site in high dosage patients. Quantification of
signal at the injection site showed that the

19

F-MRI signal decreased by approximately

50% between the two imaging time points. This suggested that DC migrated from the
initial site. However, no signal was observed in the nearby lymph nodes, likely due to the
limited sensitivity. Recently a 19F clinical protocol for imaging Stromal Vascular Fraction
(SVF) cells was published.8 With applications in breast reconstruction, the SVF is
comprised of a heterogeneous mixture of cells, with a large percentage of adipose derived
stem cells. Extensive work was performed to show no phenotypic changes from labeling.
Preferential 19F uptake was observed within some cells, with an average overall cellular
loading of 2.8±2x1012

19

F/cell. Dr. Bulte’s group was able to show a detection limit of

2x106 SVF cells implanted 5mm below the surface of the phantom, however no signal
was observed from a similar injection 1cm deep.
In this study, we sought to develop the first clinical 19F-cell tracking imaging protocol in
Canada for imaging peripheral blood mononuclear cells (PBMC). Used in the first FDA
approved anticancer vaccine, sipuleucel-T cell therapy targets castration resistant prostate
cancer. Autologous PBMC are collected and incubated with a fusion protein containing
prostatic acid phosphatase (PAP) antigen linked to granulocyte-macrophage colonystimulating factor (GM-CSF), prior to administration back into the patient.9 Success of
therapy relies on the migration of these PBMC to secondary lymphoid organs such as the
inguinal lymph nodes in the upper thigh.10 In this work we present an imaging pipeline
allowing for treatment to be first developed and optimized in pre-clinical models, then
translated to a clinical protocol. Migration of 19F-labeled PBMC to the draining lymph
node was demonstrated in mice to show that treatment could be developed and optimized
in high throughput pre-clinical models. PBMC were imaged with a clinical protocol
following injection into a ham shank phantom to simulate the human thigh.
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5.2 Methods
5.2.1

Labeling of PBMC with Cell Sense

Blood from C57Bl/6 mice was collected by venous puncture, according to animal use
protocols approved by Western University Animal Use Committee. Human peripheral
blood mononuclear cells (hPBMCs) were collected from two healthy volunteers who had
consented to a protocol approved by the University of Western Ontario Research Ethics
Board (London, ON, Canada). Approximately 100 - 160 mL of blood was drawn
following hospital procedure. In both cases, PBMCs were isolated from the blood using
gradient centrifugation via a Ficoll overlay. PBMC were washed in HBSS and resuspended in AIM-V® Medium CTS at 5x106 cells/mL in 1 well of a 12 well plate
(Falcon, Mississauga, Canada). Cells were labeled with 5mg/mL of Cell Sense (CS1000), overnight prior to administration. Following labeling, an aliquot of cells was set
aside in each experimental repetition of determination of intracellular 19F content.

5.2.2

Pre-clinical MRI of PBMC Migration

Male nu/nu mice (8-10 weeks) (n=20) were purchased from Charles River Laboratories
Inc. (Saint Constant, Canada) and housed at Robarts Research Institute at Western
University (London, Canada) in a pathogen-free barrier facility. Animal use guidelines
were followed for all experiments conducted and pre-approved by the Animal Use
Subcommittee at Western University. In each mouse, the right lymph node was pretreated with the pro-inflammatory agent IL-1b prior to PBMC administration. This agent
is expected to increase lymphatic drainage to the node, potential promoting the number of
PBMC which arrive. 5-6x106

19

F-labeled mPBMC were injected into each of the right

and left footpads, 48 hours prior to imaging. In 10 animals, mPBMC were matured with
GM-CSF, prior to administration but after 19F-labeling. By maturing the PBMC, they are
more likely to migrate to the draining lymph node and stimulate the immune system.
This produced four treatment models in the mice; 1) Untreated PMBC, 2) GM-CSF+
matured PBMC, 3) IL-1b treated lymph nodes, and 4) GM-CSF+ PBMC & IL-1b treated
LN. The frequency of signal detection and quantity of migrating cells to the lymph node
were compared between the four treatments.
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Murine imaging was performed with a 9.4T Varian small-animal MRI scanner. A 3Dbalanced steady state free precession (bSSFP) sequence was used for both 1H and

19

F

imaging. Animals were imaged alongside an agarose diluted Cell Sense reference tube of
known 19F concentration (3.33x1016 19F/µL). Mice were anesthetized with 2% isoflurane,
with breathing rate and temperature monitored throughout the scan. MRI was performed
using a dual-tuned birdcage volume coil (diameter 2.2cm, length 5.1cm), tuned to 400.2
MHz and 376.8 MHz for 1H and

19

F imaging respectively. For 1H imaging the scan

parameters were: repetition time (TR)=5.0ms, echo time (TE)=2.5ms, receiver bandwidth
(rBW)=78kHz,

flip

angle
3

resolution=200x200x200µm .

(FA)=30°,
For

19

phase

cycles

(PC)=4,

averages=3,

F imaging the parameters were: TR=4.0ms,

TE=1.9ms, rBW=25kHz, FA=70°, PC=4, averages=250, resolution=1x1x1mm3. Total
protocol time for both 1H and 19F imaging was under 90 minutes.

5.2.3

Clinical MRI Protocol

Samples were imaged with a GE MR750, 3 Tesla (T) MRI scanner equipped with a
multinuclear pre-amplifier.

Imaging was performed with two dual

1

H/19F-tuned

switchable surface coils manufactured by Clinical MR solutions. Detection sensitivity
between a large coil (25.4cm x 17.8cm) was compared to a small coil (4.3cm x 4.3cm)
with two arrays of trifluoroacetic acid (TFA) samples ranging from 0.0001%-1% with a
volume of 1mL and 15mL. Based on these results, the small coil was used for all further
experiments. Image acquisition was further optimized with hPBMC cell pellets
containing 1-10x106 cells. A 2D fast gradient echo (Fast GRE) sequence was used for 1H
imaging with the following scan parameters: TE = 2.6ms, TR = 100ms, field of view
(FOV) = 15cm x 15cm x 5cm, Image Matrix = 256x256, Slice thickness = 5mm, rBW =
83kHz, and FA = 20°. Following 1H imaging, the coil was switched to 19F-mode and the
same FOV was scanned.

19

F images were obtained with a broad-banded 3D balanced

Steady State Free Precession (bSSFP) based on the GE FIESTA-C sequence. The scan
parameters were: TE= 2.2ms, TR= 4.4ms, FOV= 15cm x 15cm x 5cm, Image matrix =
46x46, Slice thickness = 5mm, rBW= 10kHz, and FA= 70°.

19

F imaging time was 15

minutes, with a total protocol time under 30 minutes. Clinical proof-of-concept imaging
was performed with a ham shank phantom. PBMC from a healthy volunteer were labeled
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with Cell Sense (5mg/mL) for 48 hours. Realistic mock injections consisting of 1, 4.5,
10.5, and 20 x106 PBMC were performed by injecting

19

F-labeled cells into the ham

shank at two depths. A shallow intradermal injection was performed at approximately
3mm depth along with a subcutaneous injection at 1cm depth. The study was repeated
with PBMC from a second volunteer.

5.2.4

Cellular Loading Efficiency and Signal Quantification

The mean intracellular

19

F content of the PBMC mixture was determined by Nuclear

Magnetic Resonance (NMR) spectroscopy. First, a known number of cells were fixed,
then lysed through repeated cycles of sonication and freeze-thaw in solution containing
100µL 5% Triton X-100. After lysing, 300µL of D20 and 100µL of 0.1% TFA were
added to the solution. The TFA provides a reference peak for quantifying the number of
19

F spins/ cell, since NMR signal is linearly dependent on the number of

19

F atoms

present.
For in vivo MRI signal quantification, the number of PBMC was determined with Voxel
TrackerTM software. Prior to analysis, a signal correction was applied to the 19F datasets
by subtracting the signal value of the voxel containing the lowest signal in the dataset.
Once the correction was applied, the total 19F-labeled cell signal contained within a handdrawn ROI was compared to the average signal produced by a reference tube of known
concentration (3.33x1016 19F spins/µL). This information was used alongside the 19F/cell,
measured with NMR, to quantify the apparent number of cells located at the ROI.

5.3 Results
Pre-clinical imaging of mPBMC
For pre-clinical experiments either naïve PBMCs or GM-CSF exposed matured PBMCs
were injected into the footpad. In all cases 19F-signal was observed in both footpads of
the mice. The number of detected mPBMC in the draining popliteal LN is outlined in
Table 4. When signal was detected, there was no significant difference in the number of
migrating PBMC under any condition. There is no difference in the frequency of

19

F

signal detection based on either cell maturation with GM-CSF (Table 4, column 1), node
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pre-treatment with IL-1b (Table 4, column 2), or treatment with both GM-CSF and IL-1b
(Table 4, column 3). However, there was a significant difference in detection frequency
when compared to the untreated controls (Table 4, column 4).
Table 4: Summary of pre-clinical mPBMC migration to popliteal lymph nodes

Imaging of hPBMC under clinical conditions
Imaging translation was performed with a clinical-strength 3T GE MRI (Fig 24A), with a
custom-designed 4.3cm dual-tuned

19

F/1H surface coil (Fig 24B). Using the 7-channel

GE body coil, human inguinal lymph nodes could be detected as dark spheres within the
bright fat pad in the upper thigh (Fig 24C/D). 12 nodes were detected with an average
volume of 390±290mm3 and an average depth of 1.5±0.3cm. In a clinical trial, these
high quality body coil images could be used to localize the target imaging area. Prior to
image optimization, the difference in detection sensitivity between the large and small
coils was estimated with an array of TFA phantoms.

Here, the small surface coil

displayed a higher sensitivity, by almost two orders of magnitude (Fig 25A). However,
the effective imaging depth was significantly decreased, limiting the small coil to
superficial imaging sites. 19F imaging parameters were optimized on the small coil using
a series human PBMC cell pellet phantoms ranging from 1-10 x106 cells (Fig 25C).
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Figure 24: MRI provides excellent soft tissue contrast and lymph node detection.
Imaging protocol has been developed for a clinical 3T GE MRI (A). 19F imaging is
performed with a small dual-tuned surface coil placed on the patients upper thigh,
centered on the injection point (B). A coronal orientation MRI with the body coil
reveals the lymph nodes as dark spheres [blue arrow] within the fat of the upper
thigh (C). The orange dashed line indicates the location of the axial MRI slice (D).
In the axial image, the nodes were measured to be approximately 1.5cm below the
skin (D).
The pelleted cells were contained within individual Eppendorf tubes with 1% agarose
poured on top to hold them in place. Under optimum labeling conditions, with 4.2x1011
19

F/cell, as few as 1x106 PBMC could be detected (Fig 25D).

As a proof-of-concept, human PBMC were administered into a ham shank prior to
imaging with the dual-tuned surface coil (Fig 26). The ham shank Human PBMC were
19

F-labeled (mean 1.2x1011 19F/cell) and administered intradermally in 4 doses: 1.5, 4.5,

10.5 and 20 x106 cells (Fig 26A/B). With PBMC from the first donor, all injections were
detectable and quantifiable with the exception of the lowest 1.5x106 PBMC dose. In
addition, a subcutaneous injection of 4.5x106 PBMC was placed below the intradermal
dose. This site was also visible 1.2cm below the surface (Fig 26B). The

19

F/1H dual-
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tuned coil was placed on the surface above the target location, as shown (Fig 26C). 1H
images of the ham shank provided a realistic tissue model, as shown by the images of the
human thigh with the same coil (Fig 26D).

Figure 25: An array of phantoms containing 0.0001%-1% TFA in 1mL and 15mL
tubes imaged with both the large and small surface coils (A). In the sagittal proton
image of this phantom, the blue arrows indicate tubes that were detectable with
both coils, but only the small surface coil displayed sufficient sensitivity to detect
those marked by the red arrows. The lowest concentration detected, 0.001%
represents the signal on the same order of magnitude of a million PBMC. Using the
smaller coil did result in a significant increase in signal drop off with depth
compared to the larger coil (B). Cell pellet phantoms created by centrifuging 1x106,
5x106 and 10x106 Cell Sense-labeled PBMC and overlaying with 1% agarose in an
eppendorf tube (C). PBMC phantoms were placed on a saline bag and scanned at
3T and all 3 phantoms described in (C) were detected using 19F cellular MRI (D),
with a hot-iron colour scale used for 19F MRI.
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Figure 26: Human PBMC can be detected under clinical conditions following
injection into a ham shank. Cells were administered interdermally in 4 doses [yellow
arrows], 20x106 (A), 10.5x106 (not shown), 4.5x106 (B) and 1.5x106. Only the smallest
dose (1.5x106) was undetectable with our imaging parameters. An additional
4.5x106 dose was administered subcutaneously [blue arrow], which is visible at
1.2cm depth as measured with MRI. Images were performed alongside a pair of
reference tubes (R) of known 19F concentration allowing for signal quantification.
The surface coil was placed directly on the ham shank, with the reference tubes
taped inside the coil elements (C). A representative human 1H image taken with the
same parameters closely resembles the ham images in both tissue appearance and
subcutaneous fat disposition (D).
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When the experiment was repeated with PBMC from a different source labeling
efficiency was observed to be much lower (4.2x1010

19

F/cell). A comparison of the

20x106 PBMC dose is shown in Figure 27, where the images have been set to the same
window and level. Under these conditions, only the 20x106 PBMC dose was detectable
(Fig 27B).

Figure 27: Comparison of signal produced by 20 million PBMC from two different
donors. Two doses of 15x106 PBMC were prepared from different sources. In the
first, a high labeling efficiency (1.2x1011 19F/cell) was observed producing a strong
signal in the ham shank (A). The second source had a low labeling efficiency
(4.2x1010 19F/cell), resulting in a low observed signal (B).

5.4 Discussion
To our knowledge, this is the first study conducted where a primary PBMC and

19

F

cellular MRI were used to track and quantify in vivo migration in a mouse model. The
high throughput of small animal models allows for rapid testing and optimization of
treatment. Our data showed that pretreatment with either GM-CSF or IL-1b enhanced
migration to the draining LN. It is likely that some PBMC migration occurred to all of the
nodes; but in some cases the signal was insufficient to reach the detection threshold
necessary for 19F-MRI. This is particularly relevant to the untreated control group where
signal was only detected in a single node. Since treatment efficacy has been linked to the
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number of PBMC which ultimately reach the nodes,11,12 improving migration efficiency
and consistency is of the utmost importance to improving clinical outcomes.
The translational potential of 19F-MRI was investigated with a clinical 3T MRI. At 3T,
Cell Sense has been shown to have a T1 of 423ms and a T2 of 155ms, producing an ideal
bSSFP flip angle of 62°,13 which is in agreement with our observed optimal angle of 70°.
It is interesting to note that sensitivity improved with higher resolution images (data not
shown), in agreement with observations made at high-field and discussed in Section
2.2.2. For development of the clinical protocol, a ham shank phantom was used as a
mock human leg due to the tissue similarities. The largest factor governing successful
detection of PBMC was found to be the number of 19F/cell. Mean intracellular loading of
PBMC ranged from 1010 – 1011 between patients, representing an order of magnitude
difference in cell detection threshold (107 vs 106 PBMC, respectively).

Similar

differences in intracellular uptake were also observed by Dr. Ahrens et al. when labeling
DC with 19F.7 While in the development stages of clinical 19F-MRI, it may be necessary
to pre-screen patients on the basis of intracellular loading. In comparison to other clinical
19

F studies, PBMC were observed to label on average an order of magnitude lower than

DC (3.9x1012 19F/cell)7 and stromal vascular fraction cells (2.8±2x1012 19F/cell);8 which
translates into a proportional decrease in signal. Yet, despite this inherent disability, the
minimum number of detectable cells was similar compared to previous studies (DC:
~5x106, SVF: 2x106, PBMC: 4.5x106). The clinical protocol and hardware presented in
this work for imaging the ham shank represents a 10x improvement in sensitivity
compared to previous studies (table 5).
This improvement in detection sensitivity is largely due to the small size of the surface
coil used, as well as the higher number of imaging averages. We presented a significant
improvement in detection sensitivity by using a small 4.3cm x 4.3 cm compared to a
much larger 25.4cm x 17.8cm surface coil. However, this came along with a significant
decrease in imaging depth; limiting the application to surface injections and superficial
targets. Total imaging time was contained within the self-imposed clinical limit of
30minutes. However, despite these improvements sensitivity still represents the largest

100

Table 5: Overview of clinical 19F cell tracking protocols published to date

Cell Type

Dendritic Cell7

Stromal Vascular
Fraction

PBMC

8

Pulse Sequence &
Imaging Time

Year

Reported Detection
limit (19F spins)

FLASH – 9.5min

2014

~1.85x1019

bSSFP – 3.5min

2015

5.6x1018

bSSFP – 15min

2016

3.8x1017

limitation of clinical 19F-MRI. This is due to the fundamental low sensitivity of the NMR
signal, where net magnetization is only increased by 1 per 205 spins at 1.5T.

By

comparison, the high sensitivity of iron-oxide based cellular MRI is due to the indirect
detection of iron oxide through its influence on the highly abundant 1H signal. Although
magnetization increases linearly with field strength, the drive for clinical translation
limits this to 3T in most situations. Several techniques, such as hyperpolarization, have
been used with great success in other x-nuclei to temporarily increase magnetization. But
the rapid loss of magnetization with time (order of seconds) makes this inapplicable with
cell tracking. This is further complicated by the fact that only 5% of injected cells are
expected to migrate to the lymph node. Based upon the sensitivity of this protocol, we
can estimate that an initial subcutaneous injection of 90x106 PBMC would be required to
detect migration of cells to a lymph node, assuming all PBMC migrated to a single node.
Improvements in acquisition with different sequences, such as: ultrashort echo time
(UTE)-SSFP,14 advanced array coil configurations,8,15 and post processing techniques,
such as compressed sensing16 will be required to increase sensitivity to the necessary
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levels. For now, migration of PBMC must be approximated based upon the decrease in
19

F signal at the injection site over time. Finally, the minimum number of detectable cells

can be improved by increasing the amount of 19F contained within a cell. Unfortunately,
this is currently limited by phenotypic changes and decreasing viability when cells are
forced to internalize more agent. The design of novel

19

F agents will be necessary to

safely enhance uptake.
In this study, we present the highest sensitivity for 19F detection reported thus far in the
literature with a clinical protocol. Moreover, this is the first investigation to show
quantifiable signal of

19

F labeled PBMC at a depth of 1.2cm using clinical

19

F MRI

hardware and protocol, as all other studies have only detected signal of surface injected
cells.7,8 As outlined in Table 5, significant improvements in detection sensitivity have
been made each year since the first clinical 19F cellular MRI study. With the recent rapid
expansion of the field, there is strong potential for development of the necessary
technological advancements to help secure the role of

19

F in the clinical cell therapy

realm.
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Chapter 6

6

Summary and Future Work

This work is the first implementation of 19F-MRI for cell tracking in Canada. Several
advances to the field of cell tracking have been accomplished. First, Chapter 3 describes
the first time the bSSFP pulse sequence was used to quantify 19F-labeled MSC in vivo. In
Chapter 4 we demonstrate the first time dual 19F- and iron cellular MRI techniques were
used for the simultaneous tracking of the fate of a stem cell transplant and the resulting
cellular inflammatory response. Finally, in Chapter 5 we show first results of imaging of
19

F-labeled PBMC on a GE 3T clinical MRI system using a clinical imaging protocol.

Detection sensitivity was improved upon by an order of magnitude based on previously
published protocols.

6.1 Discussion and Conclusions
19

F-MRI is an emerging cell tracking technique, with excellent potential for clinical

application. This thesis has aimed to advance the development of 19F-MRI techniques
and expand applications in both the pre-clinical and clinical realms. Developing a noninvasive, non-cytotoxic, and quantifiable cellular imaging technology opens numerous
avenues of research in the fields of cellular therapy, inflammation, and cancer research.

6.1.1

Chapter 2 & 3 – Development of Pre-clinical 19F-MRI and
Tracking the Fate of Stem Cell Implants

In Chapters 2&3, pre-clinical techniques were developed for imaging and quantifying
MSC. Imaging data was supported by histology and immunohistochemistry. We were
the first to show accurate quantification with bSSFP and to describe techniques for
avoiding isoflurane background signal. The main findings were:
1) bSSFP allows for accurate quantification of cell pellets and confirmation of
administered cell dose on the day of transplant
2)

19

F-MRI can be used to identify differences in stem cell fate over time between

transplant models. In vivo quantification of the 19F-signal displayed clearance of the
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mMSCs in the two weeks following administration in the isograft model. In the
immune-compromised xenograft, signal persisted over this same time period.
3) When the natural immune system clearance is inhibited, such as in immunecompromised mice, bystander labeling of macrophages can confuse longitudinal
image interpretation.
These findings demonstrate the versatility of 19F-MRI for tracking cells. The techniques
developed and lessons learned in this project directly influenced our imaging protocols in
subsequent studies. In particular, the improvements to quantification accuracy and
avoiding isoflurane signal represent significant development milestones. Finally, the
technique was applied to assess the differences in stem cell fate between transplant
models. Here we were able to longitudinally image changes in the number of stem cells
remaining at the site of implantation. However, assessing the infiltration of immune cells
to the implant site still required the use of ex vivo immunohistochemistry; tracking this
occurrence was the primary goal of the next study.

6.1.2

Chapter 4 – Application of Dual 19F- and Iron-cellular MRI
Agents to Track the Infiltration of Immune Cells to the Site of
a Rejected Stem Cell Transplant

In chapter 4, we built on our pre-clinical imaging by demonstrating that 19F-MRI can be
combined with iron oxide cell tracking techniques to provide additional information on
the rejection of stem cell transplants. We were the first to combine stem cells labeled
with 19F in vitro with intravenous labeling of phagocytic immune cells in situ. The main
findings were:
1) Following injection of IV SPIO, signal from the 19F labeled stem cells dropped
significantly due to iron oxide induced signal quenching. The 19F-signal did not
change from this point until endpoint on day 14.
2) The signal void region, indicating the presence of inflammatory cells, extended
beyond the site of the stem cell transplant itself. No signal void was observed in the
opposite limb which had not received a stem cell transplant, or in mice which only
received a saline sham injection.
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3) Following in situ labeling of immune cells with 19F, no significant change in signal
was observed over the 14 days. This suggests there is no change in the number of
immune cells present at the transplant site following the initial influx.
These findings implement a new method for combining cellular MRI techniques to obtain
additional in vivo information. The significant decrease in both 19F and 1H signal
resulting from the influx of SPIO labeled immune cells provides a method to track
rejection and could be used as an early indicator of graft failure, without having to wait
for symptomatic analysis. Overall, this study highlights the exciting potential of
combining cellular MRI techniques to advance pre-clinical research.

6.1.3

Chapter 5 – Development of a Clinical Protocol for Imaging
19
F-labeled PBMC

In Chapter 5, we focused on translating our knowledge of 19F-MRI from the high-field,
pre-clinical 9.4T MRI to a clinical 3T system. In this study, we report the first time a 19F
clinical cell tracking protocol has been developed for a General Electric MRI system.
This is the first report of imaging the heterogeneous PBMC mixture with 19F-MRI. In
addition, we present the best detection sensitivity for a clinical protocol currently
reported in the literature and the first time cells were detected at greater than 1cm depth
in a clinical phantom. The main findings were:
1) PBMC could be imaged following administration into a ham shank with a dual-tuned
surface coil and 30minute clinical protocol. Total imaging time for this protocol was
kept under 30minutes for patient comfort; including patient positioning, localizers,
anatomical 1H, and 19F scans.
2) A detection limit of 3.8x1017 19F atoms was measured, representing approximately
4.5x106 PBMC. This is an order of magnitude higher sensitivity than previous
studies had reported. In addition, cells could be detected following a surface
intradermal injection, and at 1cm depth with a subcutaneous injection.
3) Intracellular uptake of the 19F agent was highly variable between patients,
representing more than an order of magnitude of difference in minimum number of
detectable cells. Based upon these results, in the development stage of clinical 19F-
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MRI, it may be necessary to pre-screen patients on a basis of intracellular loading
prior to study enrollment.
These findings highlight the potential for clinical application of 19F-MRI cell tracking.
The minimum detection limit of 4.5x106 PBMC is well above clinical doses applied with
sipuleucel-T therapy. In addition, by using a very small surface coil and sacrificing
imaging depth we were able to improve detection sensitivity by an order of magnitude,1
and by more than two orders over the first study published in 2014.2 Overall this work
lays the foundation necessary for approval of a 19F clinical trial at Robarts Research
Institute.

6.2 Limitations
Loss of Intracellular Label
Cellular 19F-MRI of pre-labeled cells is limited by the inability to longitudinally
determine the number of live cells, when and if bystander labeling has occurred, and the
low sensitivity. From just the images, it is impossible to determine what percentage of
signal is produced by viable, 19F-labeled therapeutic cells. Correlating 19F-signal with that
produced by bioluminescence imaging (BLI) could be used to address this limitation.
BLI detects ATP producing cells, expressing the luciferase gene. Signal is theoretically
quantitative, but severely attenuated with tissue depth. For discerning bystander labeling,
a more successful approach may lie in the combination of cellular MRI techniques, as
shown by Dr. Hitchens and discussed in chapter 4.3 It is interesting to note that in certain
circumstances 19F-MRI provides some advantage over SPIO when considering bystander
labeling. Due to the lower sensitivity, significantly more bystander labeling is necessary
at a given site before false-positive signal is detected.4 But due to this decreased
sensitivity the detection of therapeutic 19F-labeled cells can be missed if they do not reach
the detection threshold. This is of concern with partial volume effects where a low
number of cells is separated further by different voxels.
In vivo Quantification
A large number of assumptions are made when quantifying 19F-labeled cells in vivo.
Prior to cell administration, we assume the re-suspended cells are homogeneously
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distributed. If the cells are not perfectly homogenous, this influences the number of cells
injected, and more importantly, the number of cells set aside for NMR. Since
quantification is reliant on the accuracy of the intracellular 19F uptake measurement, this
is a significant potential source of error. In the images, regions of interest are selected by
the user by eye and quantification is performed on hand-drawn ROIs. Determination of
the boundary outlining noise from signal is often not concrete, and different ROI’s may
be drawn by users of differing experience. Finally, quantification assumes the signal at
the ROI is comparable to the signal at the reference tube to determine the number of 19F
atoms present. This is influenced by the different relaxation rates due to environment
from the agar reference tube and the in vivo, intracellular agent. In addition, any changes
in B1 field homogeneity would introduce additional quantification error as 19F atoms
experience different flip angles. Based upon our observations, we would approximate the
error from bSSFP 19F quantification on any individual scan to be +/- 15%. With repeated
imaging, this value has been found to converge to the expected quantification number.
Quantification of 19F signal is further hindered in the presence of iron oxide, and at only
“apparent” cell number can be measured due to the drastic differences in relaxation.
With the bSSFP sequence, SPIO quenches both 1H and 19F. The degree of quenching is
difficult to determine due to the complexity of the sequence. Dr. Hitchens has shown that
application of a UTE sequence can be used to generate a 19F image even in the presence
of iron oxide.3 However, it is not clear how the accuracy of quantification would be
affected in this case.
Clinical Protocol Optimization
Finally, the clinical protocol was optimized in a cadaverous ham shank. Although similar
in appearance to a human thigh in 1H images, there are distinct differences between the
physiology of the two. First, the skin of the ham is significantly thicker and tougher than
that of a human. This may assist in holding the injected cells in a tighter pellet following
interdermal injection. The lack of functioning immune system and active blood supply
would also hinder the movement and clearance of PBMC. In a clinical case, it may be
expected that PBMC have higher potential to disperse and migrate away from the site in
the time between injection and imaging.

109

6.3 Future Work
Future work will focus on applying the imaging techniques developed within this thesis
to pre-clinical models of disease and to the first 19F-cell tracking clinical trial in Canada.

6.3.1

Application of 19F-MRI to Pre-clinical Disease Models

This thesis focused on developing a 19F-site and techniques for application in a variety of
disease models. One such model is in correlating the presence and number of tumour
associated macrophages (TAMs) with tumourgenicity. TAMs have been shown to
promote metastasis and immune tolerance.5 Building on the techniques introduced in this
thesis, Ashley Makela (PhD Candidate) from Dr. Foster’s lab has shown 19F-MRI
provides superior information over SPIO for visualizing TAMs in vivo. The 19F-agent is
administered intravenously and labels phagocytic macrophages in situ. Information such
as the relative number of TAMs and spatial distribution throughout the tumour can be
compared with this technique.
Investigating the factors involved with the migration of labeled APCs is also a promising
direction for 19F-MRI. Future work could explore the application of antigen-loaded APC
on a tumour bearing animal. When combined with 19F-MRI, the therapeutic effects could
be correlated with the number of 19F-labeled APCs which arrive at the draining LN.
Anti-cancer treatment effects could be further optimized by adjusting the route of
delivery, dosage, APC cell-type, and pre-labeling strategies. The PBMC work is being
led by Corby Fink (PhD Candidate) and the DC work by Michael Smith (MSc Candidate)
in Dr. Dekaban’s lab.

6.3.2

Two-colour 19F-MRI for Imaging Transplant Rejection

In chapter 4, the largest limitation introduced by application of iron and 19F cellular MRI
was the inability to quantify either the stem cell transplant or the resulting inflammation
due to the negative iron contast. However, by using two spectrally different 19F-agents,
inflammation signal could be differentiated from stem cell signal. This would provide a
significant advantage over the current technique since it would allow both processes to be
quantified over time. An addition advantage could be found from the combination of two

110
19

F agents and a SPIO agent, which would allow for three distinct cell populations to be

tracked simultaneously. In combination with the new imaging technology, Magnetic
Particle Imaging (MPI), all three of these cell populations can be spatial located and
quantified.6

6.3.3

Phase-I Clinical Trial Investigating Safety and Tolerability of
19
F-labeled Human PBMC

With the establishment of a sufficiently sensitive clinical protocol, the next step is to run
a Phase I clinical trial will focus on the safety and tolerability of 19F-labeled PBMC. The
trial (ClinicalTrials.gov identifier: NCT02921373) is set to enroll 6 healthy and 6 prostate
cancer volunteers. Autologous PBMC will be collected, separated, and labeled with 19F
under Good Manufacturing Practice (GMP) conditions necessary for human
administration. Secondary outcomes of the trial will be to further optimize detection of
the injection site, and determine if LN signal can be observed in any volunteers. The trial
will be overseen by Health Canada and Western University Ethics committee.
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